阅读说明：本技术 脑膜炎球菌疫苗 (Meningococcal vaccines ) 是由 A.比奥尔希 B.布鲁内利 M.M.朱利亚尼 V.马西尼亚尼 于 2015-07-16 设计创作，主要内容包括：本发明涉及脑膜炎球菌疫苗。脑膜炎球菌疫苗可以通过包括fHbp的多个等位基因或变体来改进,以便提供对于该蛋白已知的多样性的更广覆盖度,和/或通过减少每剂量中OMV组分的量来改进。(The present invention relates to meningococcal vaccines. Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, to provide broader coverage of known diversity for the protein, and/or by reducing the amount of OMV component per dose.)

1. An immunogenic composition comprising a fusion polypeptide comprising all three of v1, v2 and v3 meningococcal fHbp, in combination with: (i) a NHBA polypeptide, (ii) a NadA polypeptide, and (iii) a meningococcal outer membrane vesicle, wherein v2 consists of SEQ ID NO:8 comprising mutations S32V and L123R and v3 consists of SEQ ID NO:9 comprising mutations S32V and L126R.

2. The immunogenic composition of claim 1, wherein the Outer Membrane Vesicles (OMVs) are present at a concentration of 5-30 μ g/ml.

3. The composition of any preceding claim, wherein:

after administration to a mouse, the fusion polypeptide can elicit antibodies that can recognize all three of: (a) a polypeptide consisting of SEQ ID NO. 4, (b) a polypeptide consisting of SEQ ID NO. 5, (c) a polypeptide consisting of SEQ ID NO. 6;

after administration to a mouse, the NHBA polypeptide can elicit an antibody that can bind to a polypeptide consisting of the amino acid sequence of SEQ ID No. 13;

and/or

After administration to a mouse, the NadA polypeptide can elicit an antibody that can bind to a polypeptide consisting of the amino acid sequence of SEQ ID No. 18.

4. The composition of any preceding claim, wherein the fHbp fusion polypeptide has the formula NH₂—A-[-X-L ]₃-B-COOH, wherein each X is a different variant fHbp sequence, L is an optional linker amino acid sequence, a is an optional N-terminal amino acid sequence, and B is an optional C-terminal amino acid sequence.

5. The composition of claim 4, wherein the variant fHbp sequence is in the order v2-v3-v1 from N-terminus to C-terminus.

6. The composition of claim 5, wherein the fusion polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 34, 36, 37, and 38.

7. The composition of any preceding claim, wherein: (a) the fHbp fusion polypeptide has an amino acid sequence of SEQ ID NO. 36 or SEQ ID NO. 38; (b) the NHBA polypeptide comprises an amino acid sequence SEQ ID NO 12; and (c) the NadA polypeptide has the amino acid sequence of SEQ ID NO 19.

8. The composition of any preceding claim, wherein the OMV is from a serogroup B strain.

9. The composition of claim 8, wherein said OMV is prepared from strain NZ 98/254.

10. The composition of any preceding claim, wherein the OMVs are present at a concentration of 10 μ g/ml to 15 μ g/ml.

11. The composition of any preceding claim, wherein the fHbp, NHBA and NadA polypeptides are present at a concentration of 50-150 μ g/ml.

12. The composition of any preceding claim, further comprising an aluminum hydroxide adjuvant.

13. Use of the immunogenic composition of any preceding claim in the manufacture of a medicament for protecting a mammal against meningococcal infection.

14. The use of claim 13, wherein the mammal is a human.

Technical Field

The present invention is in the field of meningococcal vaccination.

Background

Neisseria meningitidis (Neisseria meningitidis) Is a gram-negative capsular bacterium that colonizes the upper respiratory tract in approximately 10% of the population. Conjugate vaccines against serogroups A, C, W135 and Y are available, but the only vaccine available to protect against serogroup B is typically the BEXSERO-trap-product approved in 2013. The product comprises four main immunogenic components: factor H binding protein, 'fHbp'; heparin binding protein, NHBA; neisserial adhesin a, NadA; and Outer Membrane Vesicles (OMVs).

Disclosure of Invention

One aspect of the invention is an immunogenic composition comprising a fusion polypeptide comprising all three of v1, v2, and v3 meningococcal fHbp in combination with one or more of: (i) a NHBA polypeptide, (ii) a NadA polypeptide, and/or (iii) a meningococcal outer membrane vesicle.

A further aspect of the invention is an immunogenic composition comprising meningococcal outer membrane vesicles in combination with one or more of: (i) a NHBA polypeptide, (ii) a NadA polypeptide, and/or (iii) a fusion polypeptide comprising all three of v1, v2, and v3 meningococcal fHbp; wherein the Outer Membrane Vesicles (OMVs) are present at a concentration of 5-30 μ g/ml. In particular, fusion polypeptides comprising all three of v1, v2, and v3 meningococcal fhbps are stabilized and/or fHbp non-binding fusion polypeptides. Still more specifically, the v1 fHbp comprises a mutation at position R41, for example a R41S mutation. Still more specifically, the v2 and v3 fHbp polypeptides comprise one or more stabilizing and/or factor h (fh) non-binding mutations at the following positions numbered according to the full-length sequences (SEQ ID NOs: 2 and 3) and according to the Δ G sequences (SEQ ID NOs: 8 and 9):

a further aspect of the invention is an immunogenic composition comprising a peptide having the formula NH₂—A-[-X-L ]₃Fusion of the amino acid sequence of-B-COOHA synthetic polypeptide, wherein each X is a different variant fHbp sequence, L is an optional linker amino acid sequence, a is an optional N-terminal amino acid sequence, and B is an optional C-terminal amino acid sequence.

A further aspect of the invention is a method of protecting a mammal, such as a human, from meningococcal infection, which comprises administering an immunogenic composition according to the invention.

Drawings

Fig. 1 shows RCD curves with ratios on the y-axis (0.0 to 1.0) and SBA titers on the x-axis (0 to 256 in 16 steps). The uppermost curve is group C; the fastest group to 0.0 is S.

Figure 2 provides a schematic of the stabilized and factor h (fh) non-binding mutations introduced into v1, v2, and v3 fHbp polypeptides to produce 731S and 731 SNB fusion proteins.

FIGS. 3(a) - (g) show that compositions comprising 741-231 fusions (SEQ ID NO:10) and 1/4OMV reacted with BEXSERO^TMHigher GMTs were elicited compared to seven test strains (3a = v2, 3b = v2, 3c = v3, 3d = v3, 3e = v2, 3f = v2, 3g = v 3).

Detailed description of the invention

In order to enhance the BEXSERO-product, it would be advantageous to further enhance the coverage of the BEXSERO-product against different meningococcal strains (in the case of potential shifts and mutations that spread with the use of the vaccine) and also to reduce the occurrence of rare fever (sometimes seen when the vaccine is co-administered with conventional infant vaccines [1 ]). For these purposes, the inventors modified the BEXSERO-cell in two ways: (i) including multiple alleles or variants of fHbp, so as to provide broader coverage of known diversity for the protein; and (ii) reducing the amount of OMV component in each dose. As shown herein, these two modifications do result in improvements in the vaccine.

Thus, in a first embodiment, the invention provides an immunogenic composition comprising a fusion polypeptide comprising all three of v1, v2 and v3 meningococcal fHbp in combination with one or more of: (i) a NHBA polypeptide, (ii) a NadA polypeptide, and/or (iii) a meningococcal outer membrane vesicle.

Furthermore, in a second embodiment, the invention provides an immunogenic composition comprising meningococcal outer membrane vesicles in combination with one or more of: (i) a NHBA polypeptide, (ii) a NadA polypeptide, and/or (iii) a fusion polypeptide comprising all three of v1, v2, and v3 meningococcal fHbp; wherein the outer membrane vesicles are present at a concentration of 5-30 μ g/ml.

Similarly, in combination of these two embodiments, the invention provides an immunogenic composition comprising (i) a fusion polypeptide comprising all three of v1, v2 and v3 meningococcal fHbp, (ii) an NHBA polypeptide, (iii) a NadA polypeptide and (iv) 5-30 μ g/ml meningococcal outer membrane vesicles.

Factor H binding protein (fHbp)

Compositions of the invention may include an immunogenic fHbp polypeptide. BEXSERO products include fHbp polypeptides, and fHbps are also referred to as '741' (SEQ ID NO:2536 in reference 2; SEQ ID NO:1 herein), 'NMB1870', 'GNA1870', '3-5', 'P2086', 'LP2086', or 'ORF2086' [6-8 ]. The 3D structure of this protein is known [9, 10], and this protein has two β -barrels (β -barrels) connected by short linkers. The protective efficacy of this protein in meningococcal vaccines has been reported in a number of publications, see, for example, references 11-15. The protein is expressed in lipidated form in various strains of all serogroups. The fHbp sequence has been divided into three variants [3] (referred to herein as v1, v2 and v3) and it has been generally found that serum produced for a given variant is bactericidal against a strain expressing that variant, but that it is not active against strains expressing one of the other two variants, i.e. there is intra-variant cross-protection but no inter-variant cross-protection (except for some v2 and v3 cross-reactivity).

To increase cross-reactivity between variants, fHbp sequences have been engineered to contain specificity for all three variants [16 ]. However, instead of following this approach, the present invention utilizes a fusion polypeptide comprising all three of v1, v2, and v3 meningococcal fHbp.

v1 fHbp

The full length fHbp from strain MC58 in v1 has the following amino acid sequence (SEQ ID NO: 1):

mature lipoproteins lack the first 19 amino acids of SEQ ID NO:1 (underlined; SEQ ID NO:4 is provided, beginning with Cys-20). BEXSERO ™ product includes the ` Δ G ` form of v1 fHbp, in which the full-length sequence is truncated up to residue 26 (i.e., the polyglycine segment is removed and instead begins with Val-27), giving SEQ ID NO 7.

The v1 meningococcal fHbp used in the invention will comprise (i) a sequence having at least one amino acid sequence with SEQ ID NO 7i%Sequence identity and/or (ii) an amino acid sequence comprising a fragment of SEQ ID NO: 7.

iThe value of (b) may be selected from 80, 85, 86, 87, 88, 89,90, 91,92, 93,94, 95, 96, 97, 98, 99 or higher. It is preferably 90 (i.e., the amino acid sequence has at least 90% identity to SEQ ID NO:7) and more preferably 95.

(ii) Will typically be at least 7 amino acids long, such as 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 24, 26, 28, 40, 45, 50, 55, 60, 65, 70, 75, 80 or more consecutive amino acids from SEQ ID No. 7. The fragment will typically include at least one epitope from SEQ ID NO 7. Epitope identification and mapping was established for fHbp [ 12; 17-21]. Sharing at least 30 contiguous amino acids with SEQ ID No. 7 would be typical, and typically the v1 fHbp amino acid sequence would include several (e.g. 2,3, 4, 5 or more) fragments from SEQ ID No. 7.

In general, the v1 fHbp amino acid sequence can have at least the same amino acid sequence as SEQ ID NO. 7i%Sequence identity and includes several fragments of SEQ ID NO 7.

The v1 fHbp sequence typically includes at least one amino acid sequence that is not present in SEQ ID NO. 2 and/or at least one amino acid sequence that is not present in SEQ ID NO. 3.

After administration to a suitable host mammal, such as a mouse or human, a polypeptide used in the invention and comprising the sequence v1 can elicit antibodies that can recognize the wild-type meningococcal polypeptide consisting of SEQ ID No. 4. These antibodies will include some that will not recognize v2 or v3 polypeptides (e.g., will not recognize the wild-type meningococcal polypeptide consisting of SEQ ID NO:5 and the wild-type meningococcal polypeptide consisting of SEQ ID NO:6), although they may also include some that cross-react with v2 and/or v3 polypeptides. The antibodies are ideally bactericidal against a meningococcal strain expressing v1 fHbp, for example against the MC58 strain (see below).

v2 fHbp

The full length fHbp from strain 2996 in v2 has the following amino acid sequence (SEQ ID NO: 2):

mature lipoproteins lack the first 19 amino acids of SEQ ID NO:2 (underlined; SEQ ID NO:5 is provided), and the Δ G form of SEQ ID NO:2 lacks the first 26 amino acids (SEQ ID NO: 8).

The v2 meningococcal fHbp used in the invention will comprise (i) a sequence having at least one amino acid sequence (I) in comparison with SEQ ID NO:8j%Sequence identity and/or (ii) an amino acid sequence comprising a fragment of SEQ ID NO: 8.

jMay be selected from 80, 85, 86, 87, 88, 89,90, 91,92, 93,94, 95, 96, 97, 98, 99 or more. It is preferably 90 (i.e., the amino acid sequence has at least 90% identity to SEQ ID NO:8) and more preferably 95.

(ii) Will typically be at least 7 amino acids long, such as 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 24, 26, 28, 40, 45, 50, 55, 60, 65, 70, 75, 80 or more consecutive amino acids from SEQ ID No. 8. The fragment will typically include at least one epitope from SEQ ID NO 8. Epitope identification and mapping was established for fHbp (see above). Sharing at least 30 contiguous amino acids with SEQ ID No. 8 will be typical, and typically the v2 fHbp amino acid sequence will include several (e.g. 2,3, 4, 5 or more) fragments from SEQ ID No. 8.

In general, the v2 fHbp amino acid sequence can have at least the same amino acid sequence as SEQ ID NO. 8j%Sequence identityAnd includes several fragments of SEQ ID NO 8.

The v2 fHbp sequence typically includes at least one amino acid sequence that is not present in SEQ ID NO. 1 and/or at least one amino acid sequence that is not present in SEQ ID NO. 3.

After administration to a suitable host mammal, such as a mouse or human, a polypeptide used in the invention and comprising the sequence v2 can elicit antibodies that can recognize the wild-type meningococcal polypeptide consisting of SEQ ID NO 5. These antibodies will include some that will not recognize v1 or v3 polypeptides (e.g., will not recognize the wild-type meningococcal polypeptide consisting of SEQ ID NO:4 and the wild-type meningococcal polypeptide consisting of SEQ ID NO:6), although they may also include some that cross-react with v1 and/or v3 polypeptides. The antibody is ideally bactericidal against a meningococcal strain expressing v2 fHbp, for example against the M2091 strain (see below).

v3 fHbp

The full length fHbp from strain M1239 in v3 has the following amino acid sequence (SEQ ID NO: 3):

mature lipoproteins lack the first 19 amino acids of SEQ ID NO:3 (underlined; SEQ ID NO:6 is provided), and the Δ G form of SEQ ID NO:3 lacks the first 31 amino acids (SEQ ID NO: 9).

The v3 meningococcal fHbp used in the invention will comprise (i) a sequence having at least one amino acid sequence as set forth in SEQ ID NO 9k%Sequence identity and/or (ii) an amino acid sequence comprising a fragment of SEQ ID NO 9.

kMay be selected from 80, 85, 86, 87, 88, 89,90, 91,92, 93,94, 95, 96, 97, 98, 99 or more. It is preferably 90 (i.e., the amino acid sequence has at least 90% identity to SEQ ID NO:9) and more preferably 95.

(ii) Fragments of (a) will typically be at least 7 amino acids long, e.g., 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 24, 26, 28, 40, 45, 50, 55, 60, 65, 70, 75, 80 or more consecutive amino acids from SEQ ID No. 9. The fragment will typically include at least one epitope from SEQ ID NO 9. Epitope identification and mapping was established for fHbp (see above). Sharing at least 30 contiguous amino acids with SEQ ID No. 9 will be typical, and typically the v3 fHbp amino acid sequence will include several (e.g. 2,3, 4, 5 or more) fragments from SEQ ID No. 9.

In general, the v3 fHbp amino acid sequence can have at least the same amino acid sequence as SEQ ID NO. 9k%Sequence identity and includes several fragments of SEQ ID NO 9.

The v3 fHbp sequence typically includes at least one amino acid sequence that is not present in SEQ ID NO. 1 and/or at least one amino acid sequence that is not present in SEQ ID NO. 2.

After administration to a suitable host mammal, such as a mouse or human, a polypeptide used in the invention and comprising the sequence v3 can elicit antibodies that can recognize the wild-type meningococcal polypeptide consisting of SEQ ID No. 6. These antibodies will include some that will not recognize v1 or v2 polypeptides (e.g., will not recognize the wild-type meningococcal polypeptide consisting of SEQ ID NO:4 and the wild-type meningococcal polypeptide consisting of SEQ ID NO:5), although they may also include some that cross-react with v1 and/or v2 polypeptides. The antibodies are ideally bactericidal against meningococcal strains expressing v3 fHbp, for example against M01-240355 strain (see below).

Fusion polypeptides

The invention utilizes fusion polypeptides comprising all three of v1, v2, and v3 meningococcal fhbps. As a result, the fusion polypeptide can include at least one epitope from each of SEQ ID NOs 7, 8, and 9, and upon administration to a host mammal, can elicit antibodies that can recognize all three of: (i) a wild-type meningococcal polypeptide consisting of SEQ ID NO 4, (ii) a wild-type meningococcal polypeptide consisting of SEQ ID NO 5, and (iii) a wild-type meningococcal polypeptide consisting of SEQ ID NO 6. These antibodies are ideally bactericidal against meningococcal strains expressing v1 fHbp, meningococcal strains expressing v2 fHbp, and meningococcal strains expressing v3 fHbp (e.g. against each of MC58, M2091 and M01-240355 strains).

With reference to the definitions given above, when relevant, for the fusion polypeptide it is preferredi=j=k。

Typically, fHbp fusion polypeptides of the invention have an amino acid sequence of the formula:

NH₂—A-[-X-L-]₃-B—COOH

wherein each X is a different variant fHbp sequence, L is an optional linker amino acid sequence, a is an optional N-terminal amino acid sequence, and B is an optional C-terminal amino acid sequence.

The three X moieties are the v1, v2 and v3 sequences as discussed herein. These may be present in any order from N-terminus to C-terminus, i.e.v 1-v2-v3, v1-v3-v2, v2-v1-v3, v2-v3-v1, v3-v1-v2 or v3-v2-v 1. The most preferred sequence is v2-v3-v 1.

For [ -X-L-]In each case, the linker amino acid sequence-L-may or may not be present. The linker amino acid sequence-L-is typically short (e.g., 20 or fewer amino acids, i.e., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8,7, 6,5, 4,3, 2,1 amino acid). Examples include cloning-facilitating short peptide sequences, poly-glycine linkers (i.e., Gly _n Whereinn = 2,3, 4, 5,6, 7, 8, 9, 10 or more (SEQ ID NO: 42)) and a histidine tag (i.e., His) _n Whereinn = 3, 4, 5,6, 7, 8, 9, 10 or more (SEQ ID NO: 43)). Other suitable linker amino acid sequences will be apparent to those skilled in the art. One useful linker is GSGGGG (SEQ ID NO:22) in which the Gly-Ser dipeptide is derived fromBamHI restriction sites were formed, thus facilitating cloning and manipulation. Another useful linker is SEQ ID NO:23, which may optionally be preceded by Gly-Ser dipeptide (SEQ ID NO:24, fromBamHI) or Gly-Lys dipeptide (SEQ ID NO:25, fromHindIII)。

-a-is an optional N-terminal amino acid sequence. This is typically short (e.g., 40 or fewer amino acids, i.e., 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14)13, 12, 11, 10, 9, 8,7, 6,5, 4,3, 2,1 amino acid). Examples include leader sequences that direct protein trafficking. If X is₁Lacking its own N-terminal methionine, -A-may provide such methionine residue in the translated polypeptide (e.g., -A-is a single Met residue). Met can be at the N-terminus of a linker sequence such as SEQ ID NO:23 (i.e., SEQ ID NO: 26), or at the N-terminus of a short sequence (e.g., SEQ ID NO: 27).

-B-is an optional C-terminal amino acid sequence. This is typically short (e.g., 40 or fewer amino acids, i.e., 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8,7, 6,5, 4,3, 2,1 amino acid). Examples include sequences that direct protein trafficking, short peptide sequences that facilitate cloning or purification (e.g., comprising a histidine tag, His _n Whereinn = 3, 4, 5,6, 7, 8, 9, 10 or more (SEQ ID NO: 43)), or a sequence that enhances the stability of the polypeptide. Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art. A suitable-B-moiety is SEQ ID NO 28, where Leu-Glu upstream of the histidine tag is generated fromXhoI restriction site.

One fusion polypeptide suitable for use in the present invention comprises SEQ ID NO 10. According to the above formula, in SEQ ID NO 10, -A-is SEQ ID NO 26, X₁Is the v2 fHbp sequence (SEQ ID NO:8), -L₁Is SEQ ID NO 24, X₂Is the v3 fHbp sequence (SEQ ID NO:9), -L₂Is SEQ ID NO 22, X₃Is the v1 fHbp sequence (SEQ ID NO:7), and L₃And B is absent. The three fHbp sequences in SEQ ID NO:10 are underlined as follows:

a more preferred fusion polypeptide for use in the present invention comprises SEQ ID NO. 29. According to the above formula, in SEQ ID NO:29, -A-is SEQ ID NO:26, X₁Is the v2 fHbp sequence (SEQ ID NO:8), -L₁Is SEQ ID NO 22, X₂Is the v3 fHbp sequence (SEQ ID NO:9), -L₂Is SEQ ID NO 22, X₃Is the v1 fHbp sequence (SEQ ID NO:7), and L₃And B is absent. The three fHbp sequences in SEQ ID No. 29 are underlined as follows:

thus, the invention desirably utilizes a polypeptide having the amino acid sequence SEQ ID NO 10 or SEQ ID NO 29, but the invention can also use polypeptides comprising SEQ ID NO 10 or SEQ ID NO 29 but modified by up to 10 single amino acid changes (i.e. 1,2, 3, 4, 5,6, 7, 8, 9 or 10 single amino acid substitutions, deletions and/or insertions) provided that the polypeptide can elicit antibodies that can recognize all three of the wild-type meningococcal polypeptides of SEQ ID NO 4-6 as discussed above. Furthermore, SEQ ID NO 10 or SEQ ID NO 29 may be modified to alter the-A-portion thereof (e.g., using a substitute for SEQ ID NO 26), so a polypeptide for use in the invention may comprise SEQ ID NO 30, optionally modified by up to 10 single amino acid changes (as discussed above).

For example, SEQ ID NO 30 can be modified to introduce point mutations that disrupt the ability of each fHbp to interact with fH. For example, SEQ ID NO:30 can be mutated at residues E240, E496, and R543, thereby giving SEQ ID NO:31 (comprising mutations E240X, E496X, and R543X, wherein X is any amino acid other than the amino acid in question, i.e., E240X refers to any amino acid other than E at residue 240). A preferred embodiment of SEQ ID NO 31 is SEQ ID NO 32 (which comprises the mutations E240A, E496A, R543S). The present invention can use SEQ ID NO:31 (e.g., SEQ ID NO:32), which is optionally modified by up to 5 single amino acid changes (as discussed above), provided that residues E240, E496, and R543 are absent.

In addition, SEQ ID NO 30 can be modified to introduce point mutations that increase the stability of fHbp. For example, SEQ ID NO:30 can be mutated at residues S32, L123, S285 and L379, thereby giving SEQ ID NO:33 (which comprises mutations S32X, L123X, S285X and L379X). A preferred embodiment of SEQ ID NO 33 is SEQ ID NO 34 (which comprises the mutations S32V, L123R, S285V, L379R). The present invention can use SEQ ID NO:33 (e.g., SEQ ID NO:34), optionally modified by up to 5 single amino acid changes (as discussed above), provided that residues S32, L123, S285, and L379 are absent. One such polypeptide is SEQ ID NO:35, where the v1 sequence has been modified to include a mutation reported in reference 22, such as the 'R41S' mutation (SEQ ID NO: 36). SEQ ID NO 35 comprises the mutations S32X, L123X, S285X, L379X and R543X, and SEQ ID NO 36 comprises the mutations S32V, L123R, S285V, L379R and R543S. The designation ` R41S ` is numbered relative to the mature v1 polypeptide (SEQ ID NO:4), so for example, it is present as R543X in the SEQ ID NO:35 fusion polypeptide and as R543S in SEQ ID NO: 36.

These various methods can be combined, and thus the present invention can utilize a polypeptide comprising SEQ ID NO:37 (e.g., a polypeptide having the amino acid sequence SEQ ID NO: 38). SEQ ID NO 37 and 38 comprise the mutations S32V, L123R, E240A, S285V, L379R, E496A and R543S. SEQ ID NO 38 further comprises SEQ ID NO 26 at the N-terminus.

In a further embodiment, the present invention may use SEQ ID NO:39 (which comprises the mutations L123X and L379X), such as SEQ ID NO:40 (which comprises the mutations L123R and L379R). The invention can similarly use SEQ ID NO:39 (e.g. SEQ ID NO:40), optionally modified by up to 5 single amino acid changes (as discussed above), provided that residues L123 and L379 are absent (see e.g. SEQ ID NO:34, which differs from SEQ ID NO:40 by including two S/V substitutions as shown above). One such polypeptide is SEQ ID NO:41, wherein the v1 sequence has been modified to include the 'R41S' mutation, thus comprising L123R, L379R and R543S. In a further embodiment, when such fusion proteins are present in the compositions of the invention, the OMVs may be present at a concentration of 2.5 μ g/ml to 12.5 μ g/ml.

The amino acid residues shown for the above mutations are defined relative to the specific starting sequence. The corresponding amino acid residues in any other fHbp sequence can be readily identified by sequence alignment, for example, the amino acids: when aligned using a two-sequence alignment algorithm (e.g., Needleman-Wunsch global alignment algorithm, as described in detail below), it aligns with the amino acids mentioned herein. Typically the amino acids will be identical, but if not, the alignment will be readily identified.

fHbp is a native lipoprotein of neisseria meningitidis. It has also been found to be lipidated when expressed in E.coli with its native leader sequence or with a heterologous leader sequence. The polypeptides of the invention may have an N-terminal cysteine residue that may be lipidated, e.g., it comprises a palmitoyl group, typically forming tripalmitoyl-S-glyceroyl-cysteine. However, in a typical embodiment, the fusion polypeptide of the invention is not lipidated in the expression host (typically because the N-terminal-A-moiety does not direct lipidation).

Neisseria Heparin Binding Antigen (NHBA)

The compositions of the invention may include an immunogenic NHBA polypeptide. The NHBA antigen was included as gene NMB2132 in the published genomic sequence [23] of meningococcal serogroup B strain MC58 (GenBank accession number GI: 7227388; herein SEQ ID NO: 11). Since then the sequences of NHBA antigens from many strains have been disclosed. For example, allelic forms of NHBA can be found in fig. 5 and 15 of reference 24 and in example 13 and fig. 21 of reference 2 (SEQ ID 3179 to 3184 therein). Various immunogenic fragments of the NHBA antigen have also been reported, including the ` Δ G ` fragment of SEQ ID NO 12. Preferred NHBA antigens for use in the present invention comprise the following amino acid sequence: (a) 60% or more identity (e.g., 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO 12; and/or (b) a fragment comprising at least 'n' contiguous amino acids of SEQ ID NO 12, wherein 'n' is 7 or more (e.g., 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). (b) The preferred fragment of (A) comprises the epitope from SEQ ID NO. 12.

The most useful NHBA antigens of the invention can elicit antibodies that can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO:13 after administration to a suitable host mammal, such as a mouse or human. An advantageous NHBA antigen for use in the present invention may elicit bactericidal anti-meningococcal antibodies after administration to a mammalian subject.

A particularly preferred NHBA polypeptide for use in the present invention comprises SEQ ID NO:12, optionally modified by up to 3 single amino acid changes (i.e. 1,2 or 3 single amino acid substitutions, deletions and/or insertions), provided that the polypeptide can elicit an antibody that can bind to SEQ ID NO:13, as discussed above.

As seen in the BEXSERO ­ products, the NHBA polypeptide may usefully be present as a fusion polypeptide, e.g. fused to a NMB1030 polypeptide. In such fusion polypeptides, NMB1030 is preferably downstream of NHBA. NMB1030 from strain MC58 has GenBank accession number GI: 7226269 (SEQ ID NO:14 herein). The NMB1030 sequence used in the present invention may comprise the following amino acid sequence: (a) 60% or more identity (e.g., 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO. 14; and/or (b) a fragment comprising at least 'n' consecutive amino acids of SEQ ID NO 14, wherein 'n' is 30 or more. A useful fragment of NMB1030 is SEQ ID NO 15.

One such NHBA-NMB1030 fusion polypeptide has the amino acid sequence SEQ ID NO 16. Thus, the present invention may use SEQ ID NO 16, optionally modified by up to 3 single amino acid changes (i.e. 1,2 or 3 single amino acid substitutions, deletions and/or insertions), provided that the polypeptide can elicit an antibody that can bind to SEQ ID NO 13, as discussed above.

Neisseria adhesin A (NadA)

The compositions of the invention can include an immunogenic NadA polypeptide. The NadA antigen is included as gene NMB1994 in the published genomic sequence of meningococcal serogroup B strain MC58 [23] (GenBank accession number GI: 7227256; herein SEQ ID NO: 17). Since then the sequences of NadA antigens from many strains have been disclosed and the activity of this protein as neisserial adhesin has been well documented. Various immunogenic fragments of NadA have also been reported. Preferred NadA antigens for use in the present invention comprise the following amino acid sequence: (a) 60% or more identity (e.g., 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO 17; and/or (b) a fragment comprising at least 'n' contiguous amino acids of SEQ ID NO 17, wherein 'n' is 7 or more (e.g., 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). (b) The preferred fragment of (A) comprises the epitope from SEQ ID NO 17.

After administration to a host mammal, the most useful NadA antigens of the invention can elicit antibodies that can bind to a meningococcal polypeptide consisting of the amino acid sequence SEQ ID NO: 18. An advantageous NadA antigen for use in the present invention can elicit bactericidal anti-meningococcal antibodies after administration to a host mammal.

Particularly preferred NadA polypeptides for use in the present invention have SEQ ID NO:19, optionally modified by up to 3 single amino acid changes (i.e. 1,2 or 3 single amino acid substitutions, deletions and/or insertions), provided that the polypeptide can elicit an antibody that can bind to SEQ ID NO:18, as discussed above.

Meningococcal Outer Membrane Vesicles (OMV)

Compositions of the invention include meningococcal OMVs, i.e. any proteoliposomic vesicle obtained by disrupting or foaming (blebbing) the meningococcal outer membrane to form therefrom a vesicle that retains the protein components of the outer membrane (e.g. PorA, PorB, RmpM, Opa, Opc, Omp85, FetA/FrpB, NspA, etc.), having a diameter in the range of 50-200 nm. Thus, the term may include OMVs (sometimes referred to as "vesicles (blebs)") as well as vesicles known as microvesicles (MV [25]) or "native OMVs" ("NOMVs" [26 ]). See also references 27-33. Typical outer membrane vesicles are prepared artificially from bacteria and can be treated with detergent (e.g. with deoxycholate) or prepared by non-detergent means (see e.g. reference 37). Techniques for forming OMVs include: the bacteria are treated with bile acid salt detergents (e.g., salts of lithocholic acid, chenodeoxycholic acid, ursodeoxycholic acid, deoxycholic acid, cholic acid, ursocholic acid, etc., and sodium deoxycholate [34 and 35] is preferred for treatment of neisseria) [36] at a sufficiently high pH that the detergent does not precipitate. Other techniques can be performed using techniques such as sonication, homogenization, microfluidization, cavitation, osmotic shock, milling, French press crushing (French press), mixing, and the like, substantially in the absence of detergents [37,38 ]. Methods that do not use detergents or use low detergents can retain useful antigens such as NspA and fHbp [127 ]. Thus, OMVs for use in the invention may be prepared using an OMV extraction buffer containing about 0.5% or less, for example about 0.2%, about 0.1%, < 0.05% or even zero deoxycholate.

Vesicles known as MV and NOMV are naturally occurring membrane vesicles that form spontaneously during bacterial growth and are released into the culture medium. The MV can be obtained by: culturing neisseria in a broth medium, separating the whole cells from the smaller MVs in the broth medium (e.g., by filtration or by low speed centrifugation to pellet only the cells and not the smaller vesicles), and then collecting the MVs from the cell-depleted medium (e.g., by filtration, by differential sedimentation or aggregation of the MVs, by high speed centrifugation to pellet the MVs). Strains for producing MV can generally be selected according to the amount of MV produced in the medium, for example, neisseria with high MV production is described in references 45 and 46.

Vesicles can be prepared from bacteria that have been genetically manipulated [39-42], for example, to increase immunogenicity (e.g., overexpress immunogens), reduce toxicity, inhibit capsular polysaccharide synthesis, down-regulate PorA expression, and the like. They can be prepared from high foaming strains [43-46 ]. Vesicles from bacteria with different subtypes of class I outer membrane proteins may be used, for example, six different subtypes [47,48] using two different populations of genetically engineered vesicles (each displaying three subtypes), or nine different subtypes using three different populations of genetically engineered vesicles (each displaying three subtypes), etc. Useful subtypes include: p1.7, 16; p1.5-1, 2-2; p1.19, 15-1; p1.5-2, 10; p1.12-1, 13; p1.7-2, 4; p1.22, 14; p1.7-1, 1; p1.18-1,3, 6. In general, however, it is preferred for the present invention that the OMVs are prepared from wild-type meningococcal strains.

Thus, vesicles used in the present invention may be prepared from any wild-type meningococcal strain. The vesicles are typically from a serogroup B strain, but it is also possible to prepare vesicles from serogroups other than B (e.g. reference 36 discloses a method for serogroup a) such as A, C, W135 or Y. The strain may be of any serotype (e.g., 1, 2a, 2b, 4, 14, 15, 16, etc.), any serosubtype (e.g., P1.4), and any immunotype (e.g., L1; L2; L3; L3, 7; L3,7, 9; L10; etc.). The meningococcus may be from any suitable lineage, including highly invasive and highly virulent lineages, for example any one of the following seven highly virulent lineages: subgroup I; subgroup III; subgroup IV-1; ET-5 complex group (complex); ET-37 complex group; cluster a 4; lineage 3. Most preferably, the OMV is prepared from strain NZ98/254 or another strain having the P1.4 PorA serosubtype. The present invention advantageously uses the same OMV prepared from strain NZ98/254 as used in the BEXSERO and MENZB-chamber products.

Vesicles will typically include meningococcal LOS (also known as LPS), but the pyrogenic effect of LOS in OMVs is much lower than that seen with the same amount of purified LOS, and adsorption of OMVs to aluminium hydroxide further reduces pyrogenicity. LOS levels are expressed in international units of endotoxin (IU) and can be measured by the LAL assay (limulus amebocyte lysate). Preferably, LOS is present at less than 2000 IU/μ g OMV protein.

When LOS is present in the vesicle, the vesicle can be treated to link its LOS and protein components ("intravesicle" conjugation [49 ]).

One useful method for OMV purification is described in reference 50 and involves ultrafiltration of crude OMV, rather than high speed centrifugation. The method may involve a step of ultracentrifugation after the ultrafiltration is performed. OMVs may also be purified using a two stage size filtration process as described in reference 51.

OMVs may usefully be suspended in a sucrose solution after they have been prepared.

Combination of

The compositions of the present invention may include each of the following: (a) a fusion polypeptide comprising all three of v1, v2, and v3 meningococcal fHbp, (b) a NHBA polypeptide, (c) a NadA polypeptide, and (d) an OMV.

In such a combination: (a) the fHbp fusion polypeptide desirably comprises the amino acid sequence SEQ ID NO:10, but it is optionally modified by up to 10 single amino acid changes, as discussed above; (b) the NHBA polypeptide desirably comprises the amino acid sequence SEQ ID NO 12, but is optionally modified by up to 3 single amino acid changes, as discussed above; and (c) the NadA polypeptide desirably comprises the amino acid sequence SEQ ID NO:19, but which is optionally modified by up to 3 single amino acid changes, as discussed above.

More preferably: (a) the fHbp fusion polypeptide has an amino acid sequence of SEQ ID NO 10; (b) the NHBA polypeptide comprises the amino acid sequence SEQ ID NO 12; and (c) the NadA polypeptide has the amino acid sequence SEQ ID NO 19.

Even more preferably: (a) the fHbp fusion polypeptide has an amino acid sequence of SEQ ID NO 10; (b) the NHBA polypeptide has an amino acid sequence of SEQ ID NO 16; and (c) the NadA polypeptide has the amino acid sequence SEQ ID NO 19.

The polypeptide in the compositions of the invention may be present at any concentration that results in an effective immune response in the host. Such administration can be established by routine testing, particularly in view of the guidance provided by the BEXSERO ™ product having fHbp, NHBA and NadA polypeptides each present at 100. mu.g/ml. Thus, the fHbp, NHBA and/or NadA polypeptides may each be present in the compositions of the invention at a concentration of 20 μ g/ml to 400 μ g/ml, such as 50-150 μ g/ml, 80-120 μ g/ml or about 100 μ g/ml. Antigen concentration is readily quantified by standard protein assays.

Similarly, OMVs in the compositions of the invention may be present at any concentration that results in an effective immune response in the host. This administration may be established by routine testing, particularly in view of the guidance provided by the BEXSERO ™ product in which OMVs are present at 50 μ g/ml. Thus, according to the first embodiment of the invention, the OMVs may be present in the composition at a concentration of from 20 μ g/ml to 100 μ g/ml, such as 30-75 μ g/ml, 40-60 μ g/ml or ideally about 50 μ g/ml. However, in a second embodiment of the invention, the OMVs are present at a lower concentration (i.e. from 5 to 30 mug/ml, for example from 10 to 15 mug/ml or ideally about 12.5 mug/ml). In certain embodiments, the OMVs are present at lower concentrations of 2.5 to 12.5 μ g/ml, e.g., 2.5 μ g/ml, 3.0 μ g/ml, 3.5 μ g/ml, 4.0 μ g/ml, 4.5 μ g/ml, 5.0 μ g/ml, 5.5 μ g/ml, 6.0 μ g/ml, 6.5 μ g/ml, 7.0 μ g/ml, 7.5 μ g/ml, 8.0 μ g/ml, 8.5 μ g/ml, 9.0 μ g/ml, 9.5 μ g/ml, and 10 μ g/ml.

The amount and concentration of OMVs in the compositions of the invention are defined in the same way as in the BEXSERO ™ product, i.e.by reference to their total protein content. This can be assessed using various assays, for example, reference 29 discloses the use of the Folin-Lowry assay. Total protein can be determined according to european pharmacopoeia Ph. eur. assay 2.5.33 using any of the seven pharmacopoeia methods. Method 2 provides a Lowry test, which is preferred. Thus, the composition of the second embodiment of the invention comprises OMVs having 5-30 μ g/ml total protein.

Polypeptides

The polypeptides of the invention can be prepared by various means, such as by chemical synthesis (at least in part), by digestion of longer polypeptides using proteases, by translation from RNA, by purification from cell culture (e.g., from recombinant expression or from neisseria meningitidis cultures), and the like. Heterologous expression in an E.coli host is a preferred expression pathway.

The polypeptides of the invention are desirably at least 100 amino acids long, e.g., 150aa, 175aa, 200aa, 225aa or longer. For example, fHbp fusion polypeptides are typically at least 500aa long, NHBA polypeptides are typically at least 400aa long, and NadA polypeptides are typically at least 250aa long.

Preferably, the polypeptide is prepared in substantially pure or substantially isolated form (i.e., substantially free of other neisserial or host cell polypeptides). Typically, the polypeptide is provided in a non-naturally occurring environment, e.g., it is separated from its naturally occurring environment. In certain embodiments, the polypeptide is present in an enriched form compared to the starting materialIn the composition. Thus, a purified polypeptide is provided, wherein purified means that the polypeptide is present in a composition that is substantially free of other expressed polypeptides, wherein substantially free means that more than 50% of the total polypeptide of the composition (e.g., such as>75%、>80%、>90%、>95% or>99%) is a polypeptide of the invention.

The polypeptide may take various forms (e.g., native, fusion, non-glycosylated, lipidated, disulfide-bonded, etc.).

Sequences such as SEQ ID NO 19 do not include the N-terminal methionine. If the polypeptide of the invention is produced by translation in a biological host, an initiation codon is required which will provide the N-terminal methionine in most hosts. Thus, the polypeptide of the invention will comprise, at least in the nascent stage, a methionine residue upstream of said SEQ ID NO sequence.

In some embodiments, the polypeptide in the compositions of the invention may include an N-terminal sequence upstream of the fHbp, NHBA or NadA polypeptide sequence (as appropriate). In some embodiments, the polypeptide has a single methionine at the N-terminus followed by the amino acid sequence of the relevant immunogen; in other embodiments, longer upstream sequences may be used. Such upstream sequences may be shorter (e.g., 40 or fewer amino acids, i.e., 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8,7, 6,5, 4,3, 2,1 amino acid). Examples include a leader sequence to direct protein transport, or a short peptide sequence (e.g., a histidine tag, His) to facilitate cloning or purification _n Whereinn4, 5,6, 7, 8, 9, 10 or more (SEQ ID NO: 44)).

The polypeptides of the invention may also include amino acids downstream of the last amino acid of the fHbp, NHBA or NadA (as appropriate) amino acid sequence. Such C-terminal extensions may be shorter (e.g., 40 or fewer amino acids, i.e., 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11,10. 9, 8,7, 6,5, 4,3, 2,1 amino acid). Examples include sequences that direct protein trafficking, short peptide sequences that facilitate cloning or purification (e.g., comprising a histidine tag, His _n Whereinn4, 5,6, 7, 8, 9, 10 or more (SEQ ID NO:44)), or a sequence that enhances the stability of the polypeptide. Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.

The term "polypeptide" refers to a polymer of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The term also encompasses amino acid polymers that are modified either naturally or by intervention; the intervention is, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation or any other manipulation or modification, such as conjugation to a labeling component. The definition also includes, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. The polypeptide may exist as a single chain or an associated chain.

The polypeptides of the invention are preferably recombinantly expressed in a heterologous host (e.g., in e.coli), then purified, then combined with OMVs and formulated to provide the compositions of the invention.

In some embodiments, the polypeptide comprises an amino acid sequence as described above, except that up to 10 (i.e., 1,2, 3, 4, 5,6, 7, 8, 9, or 10) amino acids at the N-terminus and/or up to 10 (i.e., 1,2, 3, 4, 5,6, 7, 8, 9, or 10) amino acids at the C-terminus are deleted.

Bactericidal response

As mentioned above, preferred polypeptides and compositions of the invention can elicit an antibody response against meningococcal bactericides. The bactericidal antibody response is conveniently measured after immunization of mice and is a standard indicator of vaccine efficacy (see, e.g., end-note 14 of reference 52; also reference 53). Thus, the antibodies are bactericidal against the test strain in a suitable Serum Bactericidal Assay (SBA).

Fusion of fHbp polypeptides may preferably elicit bactericidal antibody responses against meningococcal strains expressing v1 fHbp, meningococcal strains expressing v2 fHbp and meningococcal strains expressing v3 fHbp. A suitable v1 strain for SBA testing is MC58, which is widely available (e.g., ATCC BAA-335), and is the strain sequenced in reference 23. A suitable v2 strain for SBA testing is M2091(ATCC 13091). A suitable v3 strain for SBA testing is M01-240355, which is a neisserial MLST reference strain (ID 19265 in reference 54) that has been fully sequenced (see EMBL ID CP002422 [55 ]).

Thus, preferred fHbp fusion polypeptides can elicit antibodies in mice that are bactericidal against each of strains MC58, M2091, and M01-240355 in a serum bactericidal assay. For example, the compositions of the present invention can provide>Serum bactericidal titer 1:4 (using a Goldschneider assay with human complement [ 56-58)]) And/or provide>Serum bactericidal titer 1:128 (using baby rabbit complement).

Immunization

The polypeptides as discussed above may be used as active ingredients of immunogenic compositions, so the present invention provides immunogenic compositions (e.g. vaccines) of the invention comprising the polypeptides as discussed above.

The invention also provides a method of raising an antibody response in a mammal, such as a mouse or a human, comprising administering to the mammal an immunogenic composition of the invention. The antibody response is preferably a protective and/or bactericidal antibody response. The invention also provides compositions of the invention, for use in such methods.

The invention also provides a method for protecting a mammal, such as a mouse or a human, from infection by neisseria (e.g. meningococcus) comprising administering to the mammal an immunogenic composition of the invention.

The invention provides a composition of the invention for use as a medicament (e.g. as an immunogenic composition or as a vaccine). In one embodiment, it also provides a fusion polypeptide comprising all three of v1, v2, and v3 meningococcal fHbp and one or more of: (i) use of a NHBA polypeptide, (ii) a NadA polypeptide and/or (iii) a meningococcal outer membrane vesicle in the manufacture of a medicament for preventing neisserial (e.g. meningococcal) infection in a mammal. In another embodiment, the invention provides meningococcal outer membrane vesicles and one or more of: (i) use of an NHBA polypeptide, (ii) a NadA polypeptide and/or (iii) a fusion polypeptide comprising all three of v1, v2 and v3 meningococcal fHbp in the manufacture of a medicament for preventing neisserial (e.g. meningococcal) infection in a mammal, wherein the concentration of outer membrane vesicles in the medicament is between 5-30 μ g/ml.

The mammal is preferably a human. The human may be an adult or preferably a child. When the vaccine is for prophylactic use, the human is preferably a child (e.g. a toddler or infant); when the vaccine is for therapeutic use, the human is preferably an adult. Vaccines intended for children may also be administered to adults, for example, to assess safety, dosage, immunogenicity, and the like.

The uses and methods are particularly useful for the prevention/treatment of diseases including, but not limited to, meningitis (particularly bacterial meningitis, such as meningococcal meningitis) and bacteremia. For example, they are suitable for actively immunizing individuals against invasive meningococcal disease caused by neisseria meningitidis (e.g. in serogroup B).

The efficacy of therapeutic treatment can be tested by monitoring neisserial infection after administration of the composition of the invention. The efficacy of prophylactic treatment can be tested by monitoring the immune response against fHbp, NHBA, NadA and PorA (as appropriate) after administration of the composition. The immunogenicity of the compositions of the invention can be determined by administering them to test subjects (e.g., children at 12-16 months of age, or animal models) and then determining standard parameters, including Serum Bactericidal Antibodies (SBA) and ELISA titers (GMT). These immune responses are typically determined about 4 weeks after administration of the composition and compared to values determined prior to administration of the composition. An SBA increase of at least 4-fold or 8-fold is preferred. When more than one dose of the composition is administered, more than one post-administration determination may be made.

Preferred compositions of the invention can confer antibody titers in patients that are superior to the criteria for seroprotection of each antigenic component for an acceptable percentage of human subjects. Antigens with such relevant antibody titers above which the host is considered to be seroconverted for the antigen are well known, and such titers are published by tissues such as WHO. Preferably more than 80% of samples of statistically significant subjects are seroconverted, more preferably more than 90%, still more preferably more than 93%, most preferably 96-100%.

The invention may be used to elicit systemic and/or mucosal immunity.

The compositions of the invention will generally be administered directly to the patient. Direct delivery can be accomplished by parenteral injection (e.g., subcutaneous, intraperitoneal, intravenous, intramuscular, or to the interstitial space), or by rectal, oral, vaginal, topical, transdermal, intranasal, ocular, otic, pulmonary, or other mucosal administration. Intramuscular administration is preferably carried out in the thigh or upper arm. The injection may be via a needle (e.g., a hypodermic needle), but alternatively a needle-free injection may be used. Intramuscular doses are usually about 0.5ml (e.g., as seen in the BEXSERO. RTM. product).

The dose treatment may be a single dose schedule or a multiple dose schedule. Multiple doses may be used for the primary immunization schedule and/or the booster immunization schedule. The primary dosage schedule may be followed by a booster dosage schedule. Suitable timing between priming doses (e.g., between 4-16 weeks) and between priming and boosting can be routinely determined. For example, depending on the subject (e.g., an infant or otherwise), the BEXSERO-product is administered as two or three doses, taking care to be separated by less than 1 month or not less than 2 months.

The immunogenic compositions of the invention will generally include a pharmaceutically acceptable carrier, which may be any substance that does not itself induce the production of antibodies harmful to the patient receiving the composition, and may be administered without undue toxicity. Pharmaceutically acceptable carriers may include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances and the like may also be present in such vehicles. A sufficient discussion of suitable sports can be found in reference 59. For example, BEXSERO ™ products include sodium chloride, histidine, sucrose, aluminum hydroxide and water for injection.

Neisserial infections affect various regions of the body and so the compositions of the invention may be prepared in a variety of forms. For example, the compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution or suspension in a liquid vehicle prior to injection may also be prepared. Compositions suitable for parenteral injection (e.g., to muscle) are most preferred.

The composition is preferably sterile. It is preferably pyrogen free. It is preferably buffered, for example between pH 6 and pH 8, typically around pH 7. Histidine buffer [60] is preferably used when the composition comprises an aluminium hydroxide salt. The compositions of the present invention may be isotonic with respect to humans.

The immunogenic composition comprises an immunologically effective amount of the immunogen, as well as any other specified components, as desired. By "immunologically effective amount" is meant that the amount administered to an individual in a single dose or as part of a series of doses is effective for treatment or prevention. The amount will vary depending on the health and physical condition of the individual to be treated, the age of the individual to be treated, the classification group (e.g., non-human primate, etc.), the ability of the individual's immune system to synthesize antibodies, the degree of protection desired, the vaccine formulation, the treating physician's assessment of the medical condition, and other relevant factors. It is expected that the amounts will fall within a relatively wide range that can be determined by routine experimentation. The dose therapy may be a single dose schedule or a multiple dose schedule (e.g., including booster doses). The compositions may be administered in combination with other immunomodulators.

Adjuvants that may be used in the compositions of the present invention include, but are not limited to, insoluble metal salts, oil-in-water emulsions (e.g., MF59 or AS03, both containing squalene), saponins, non-toxic derivatives of LPS (such AS monophosphoryl lipid a or 3-O-deacylated MPL), immunostimulatory oligonucleotides, detoxified bacterial ADP-ribosylating toxins, microparticles, liposomes, imidazoquinolones (imidazoquinolones), or mixtures thereof. Other substances acting as immunostimulants are disclosed in chapter 7 of reference 61.

The use of aluminium hydroxide and/or aluminium phosphate adjuvants is particularly preferred, and polypeptides are typically adsorbed to these salts. These salts include oxyhydroxides and hydroxyphosphates (see, e.g., references 61, chapters 8 and 9). The salt may take any suitable form (e.g., gel, crystalline, amorphous, etc.). Al (Al)⁺⁺⁺Should be such that<1 mg/dose is present.

The most preferred adjuvant is aluminum hydroxide, as used in the BEXSERO ™ product. The polypeptides and OMVs of the compositions of the invention may be adsorbed to the adjuvant, as seen in BEXSERO ™ products. The aluminum hydroxide may be present at about 1 mg/ml Al⁺⁺⁺(i.e., 0.5mg/0.5ml dose) was included.

Other antigenic Components

Compositions of the invention may comprise other meningococcal polypeptide immunogens in addition to fHbp, NHBA, NadA and/or OMV. For example, it may include one or more of NspA, App, NhhA, HmbR, and the like.

The compositions of the invention may also include a '936' antigen. 936 antigen as gene NMB2091 was included in the published genomic sequence of meningococcal serogroup B strain MC58 [23] (here SEQ ID NO: 20). A preferred 936 antigen for use in the present invention comprises the amino acid sequence: (a) 50% or more identity (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 21; and/or (b) a fragment comprising at least 'n' contiguous amino acids of SEQ ID NO 21, wherein 'n' is 7 or more (e.g., 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). (b) The preferred fragment of (A) comprises the epitope from SEQ ID NO: 21. Following administration to a host mammal, the most useful 936 antigens of the invention can elicit antibodies that can bind to a meningococcal polypeptide consisting of the amino acid sequence of SEQ ID NO: 20. 936 antigen is a good fusion partner for fHbp (see, e.g., references 62 and 63).

In addition to meningococcal polypeptide antigens, the compositions may include antigens for immunisation against other diseases or infections. For example, the composition may include one or more of the following additional antigens:

saccharide antigens from neisseria meningitidis serogroups A, C, W135 and/or Y, such as saccharides from serogroup C (see also reference 65) or saccharides from reference 66 as disclosed in reference 64.

From Streptococcus pneumoniae: (Streptococcus pneumoniae) Sugar antigens of [ e.g., 67, 68, 69 ]]。

-an antigen from a hepatitis a virus, such as an inactivated virus [ e.g. 70, 71 ].

-antigens from hepatitis b virus, such as surface and/or core antigens [ e.g. 71, 72 ].

Diphtheria antigens, such as diphtheria toxoid [ e.g. chapter 3 of reference 73]E.g. CRM₁₉₇Mutants [ e.g. 74]。

Tetanus antigens, such as tetanus toxoid (e.g. chapter 4 of reference 73).

From Bordetella pertussis (B.Bordetella pertussis) Such as pertussis holotoxin (PT) and Filamentous Hemagglutinin (FHA) from bordetella pertussis, optionally in combination with pertactin and/or agglutinogens 2 and 3 (e.g. references 75 and 76).

From Haemophilus influenzae B (B: (B))Haemophilus influenzaeB) Saccharide antigens of [ e.g. 65]]。

Polio antigen [ e.g. 77, 78], such as IPV.

Measles, mumps and/or rubella antigens (e.g. chapters 9, 10 and 11 of reference 73).

Influenza antigens (e.g. chapter 19 of reference 73), such as hemagglutinin and/or neuraminidase surface proteins.

From Moraxella catarrhalis (A)Moraxella catarrhalis) Antigen of [ e.g. 79 ]]。

From Streptococcus agalactiae (Streptococcus agalactiae) Protein antigens of (group B Streptococci)[ e.g. 80, 81 ]]。

From Streptococcus agalactiae (Streptococcus agalactiae) Carbohydrate antigen of (group B Streptococcus).

From Streptococcus pyogenes (Streptococcus pyogenes) Antigens of (group A Streptococci) [ e.g. 81, 82, 83]。

From Staphylococcus aureus (S.) (Staphylococcus aureus) Antigen of [ e.g. 84 ]]。

The composition may comprise one or more of these other antigens.

If desired, toxic protein antigens may be detoxified (e.g. pertussis toxin detoxified by chemical and/or genetic means [76 ]).

When diphtheria antigen is included in the composition, tetanus antigen and pertussis antigen are preferably also included. Similarly, when tetanus antigen is included, diphtheria and pertussis antigens are preferably also included. Similarly, where pertussis antigens are included, diphtheria and tetanus antigens are preferably also included. DTP combinations are therefore preferred.

The saccharide antigen is preferably in the form of a conjugate. The carrier protein of the conjugate is discussed in more detail below.

The antigens in the composition are typically each present at a concentration of at least 1. mu.g/ml. Generally, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.

The immunogenic compositions of the invention can be used therapeutically (i.e., to treat an existing infection) or prophylactically (i.e., to prevent future infections).

As an alternative to the use of a protein antigen in the immunogenic composition of the invention, a nucleic acid encoding the antigen (which may be RNA, such as self-replicating RNA, or DNA, such as a plasmid) may be used.

In some embodiments, compositions of the invention comprise conjugated capsular saccharide antigens from 1,2, 3 or 4 of meningococcal serogroups A, C, W135 and Y. In other embodiments, the compositions of the invention comprise at least one conjugated pneumococcal capsular saccharide antigen.

Meningococcal serogroups Y, W135, C and A

Current serogroup C vaccines (MENJUGATE [64, 85 ]]"MENINGITEC" and NEISVAC-C "cassettes comprise conjugated saccharides. MENJUGATE and Meningitemengitate having the same₁₉₇Carrier conjugated oligosaccharide antigen, while NEISVAC-C-antibody uses the entire polysaccharide conjugated to tetanus toxoid carrier (de-O-acetylation). The meneutra ™ vaccine contains conjugated capsular saccharide antigens from each of serogroups Y, W135, C and a.

Compositions of the invention may include capsular saccharide antigens from one or more of meningococcal serogroups Y, W135, C and a, wherein the antigens are conjugated to a carrier protein and/or are oligosaccharides. For example, the composition may comprise a compound from: serogroup C; serogroups a and C; serogroups A, C and W135; serogroups A, C and Y; serogroups C, W135 and Y; or capsular saccharide antigens from all four of serogroups A, C, W135 and Y.

Typical amounts of each meningococcal saccharide antigen are 1 μ g to 20 μ g per dose, for example, about 1 μ g, about 2.5 μ g, about 4 μ g, about 5 μ g or about 10 μ g (expressed as saccharide).

When the mixture comprises capsular saccharides from serogroups a and C, the ratio (w/w) of MenA saccharide to MenC saccharide may be greater than 1 (e.g., 2:1, 3:1, 4:1, 5:1, 10:1 or higher). Where the mixture comprises capsular saccharides from serogroup Y and one or both of serogroups C and W135, the ratio of MenY saccharide to MenW135 saccharide (W/W) may be greater than 1 (e.g., 2:1, 3:1, 4:1, 5:1, 10:1 or higher) and/or the ratio of MenY saccharide to MenC saccharide (W/W) may be less than 1 (e.g., 1:2, 1:3, 1:4, 1:5 or lower). Preferred ratios (W/W) of sugars from serogroups A: C: W135: Y are: 1:1:1: 1; 1:1:1: 2; 2:1:1: 1; 4:2:1: 1; 8:4:2: 1; 4:2:1: 2; 8:4:1: 2; 4:2:2: 1; 2:2:1: 1; 4:4:2: 1; 2:2:1: 2; 4:4:1: 2; and 2:2:2: 1. Preferred ratios of sugars from serogroup C: W135: Y (W/W) are: 1:1: 1; 1:1: 2; 1:1: 1; 2:1: 1; 4:2: 1; 2:1: 2; 4:1: 2; 2:2: 1; and 2:1: 1. Preferably, substantially equal masses of each sugar are used.

Capsular saccharides in the form of oligosaccharides may be used. These are conveniently formed by: the purified capsular polysaccharide is fragmented (e.g., by hydrolysis), usually followed by purification of fragments of the desired size.

Fragmentation of the polysaccharide is preferably performed such that the final average Degree of Polymerization (DP) of the oligosaccharides is less than 30 (e.g., 10 to 20, preferably about 10 for serogroup A; 15 to 25, preferably about 15-20 for serogroups W135 and Y; 12 to 22 for serogroup C; etc.). DP can be conveniently measured by ion exchange chromatography or by colorimetric assays [86 ].

If hydrolysis is performed, the hydrolysate is typically sieved to remove short length oligosaccharides [65 ]. This can be achieved in various ways such as ultrafiltration and subsequent ion exchange chromatography. For serogroup a, it is preferred to remove oligosaccharides with a degree of polymerization of less than or equal to about 6; for serogroups W135 and Y, oligosaccharides with a degree of polymerization less than about 4 are preferably removed.

Preferred MenC carbohydrate antigens, as used in menjuate ­ gaves, are disclosed in reference 85.

Covalent conjugation

Capsular saccharides in compositions of the invention are typically conjugated to a carrier protein. Typically, conjugation enhances the immunogenicity of the saccharide, as the conjugation can convert the saccharide from a T-independent antigen to a T-dependent antigen, thus eliciting an immunological memory. Conjugation is particularly useful for pediatric vaccines and is a well known technique.

Typical carrier proteins are bacterial toxins such as diphtheria or tetanus toxins or toxoids or mutants thereof. CRM₁₉₇Diphtheria toxin mutant [87]Are useful and vectors in PREVNAR ™ products. Other suitable carrier proteins include the Neisseria meningitidis outer membrane protein complex [88]Synthetic peptides [89,90 ]]Heat shock protein [91,92 ]]Pertussis proteins [93,94 ]]Cytokine [95 ]]Lymphokines [95 ]]Hormone [95 ]]Growth factor [95 ]]Human CD4 comprising multiple antigens derived from various pathogens⁺Artificial proteins for T cell epitopes [96]Such as N19[97 ]]From Haemophilus influenzae (b), (c), (d)H.influenzae) Protein D [98-100 ]]Pneumolysin [101 ]]Or nontoxic derivatives thereof [102]Pneumococcal surface protein PspA [103 ]]Ferritin (104)]From Clostridium difficile (C.difficile) ((C.difficile))C.difficile) Toxin A or B [105 ] of]Recombinant Pseudomonas aeruginosaP. aeruginosa) Extracellular protein A (rEPA) [106]And the like.

Any suitable conjugation reaction may be used, with any suitable linker if necessary.

The saccharide will typically be activated or functionalized prior to conjugation. Activation may involve, for example, cyanating agents (cyanating agents), such as CDAP (e.g., 1-cyano-4-dimethylamino pyridinium tetrafluoroborate) [107, 108, etc. ]). Other suitable techniques use carbodiimides, hydrazides, active esters, norbornane (norbomane), p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, TSTU, and the like.

The attachment via the linker group can be performed using any known procedure, such as the procedures described in references 109 and 110. One type of linkage involves reductive amination of the polysaccharide, coupling the resulting amino group to one end of an adipic acid linker group, and then coupling the protein to the other end of the adipic acid linker group [111, 112 ]]. Other linkers include B-propionamido [113 ]]Nitrophenyl-ethylamine [114]]Halogenated acyl halide [115]Glycosidic linkage [116]6-aminocaproic acid [117]]、ADH[118]、C₄To C₁₂Portion [119]]And the like. As an alternative to using a linker, a direct connection may be used. Direct linkage to the protein may include oxidation of the polysaccharide followed by reductive amination with the protein as described, for example, in references 120 and 121.

The following methods are preferably involved: introduction of amino groups into sugars (e.g. by using-NH)₂Replacing the terminal = O group), followed by derivatization with an adipic acid diester (e.g., adipic acid N-hydroxysuccinimidyl diester), and reaction with a carrier protein. Another preferred reaction uses a CDAP-activating protein D vector, for example for MenA or MenC.

General concepts

The term "comprising" encompasses "including" as well as "consisting of … …," e.g., a composition "comprising" X may consist of X alone or may include additional substances, such as X + Y. References to "comprising" (or "comprises", etc.) may optionally be replaced with references to "consisting of" (or "consisting of …", etc.).

And a numerical valuexThe relative term "about" is optional and means, for examplex±10％。

The word "substantially" does not exclude "completely", e.g., a composition that is "substantially free" of Y may be completely free of Y. The word "substantially" may be omitted from the definition of the invention, if necessary.

"sequence identity" is preferably determined by the Needleman-Wunsch Global alignment Algorithm [122 ]]Determined using default parameters (e.g., gap open penalty of 10.0 and gap extension penalty of 0.5, using the EBLOSUM62 scoring matrix). In EMBOSS software packagesneedleThe tool conveniently performs the algorithm [123 ]]. When applied to refer to sequence identity to a particular SEQ ID, the identity should be calculated over the full length of the SEQ ID.

Serogroup followed by meningococcal classification includes serotype, serosubtype, and then immunotype, and standard nomenclature lists serogroup, serotype, serosubtype, and immunotype, each separated by a colon, e.g., B:4: P1.15: L3,7, 9. Within serogroup B, some lineages often cause disease (highly aggressive), some cause a more severe form of disease than others (highly virulent), and others cause disease very rarely. Seven highly virulent lineages were identified, subpopulations I, III and IV-1, ET-5 complex, ET-37 complex, A4 cluster and lineage 3. These have been defined by multi-site enzyme electrophoresis (MLEE), but multi-site sequence typing (MLST) has also been used to classify meningococci. The four major high virulence clusters are the ST32, ST44, ST8 and ST11 complexes.

Detailed Description

The invention also relates to the following technical scheme:

1. an immunogenic composition comprising a fusion polypeptide comprising all three of v1, v2 and v3 meningococcal fHbp, in combination with one or more of: (i) a NHBA polypeptide, (ii) a NadA polypeptide, and/or (iii) a meningococcal outer membrane vesicle.

2. An immunogenic composition comprising a meningococcal outer membrane vesicle in combination with one or more of: (i) a NHBA polypeptide, (ii) a NadA polypeptide, and/or (iii) a fusion polypeptide comprising all three of v1, v2, and v3 meningococcal fHbp; wherein the Outer Membrane Vesicles (OMVs) are present at a concentration of 5-30 μ g/ml.

3. The composition of embodiment 1 or embodiment 2, comprising (i) a fusion polypeptide comprising all three of v1, v2, and v3 meningococcal fHbp, (ii) a NHBA polypeptide, (iii) a NadA polypeptide, and (iv) a meningococcal outer membrane vesicle.

4. The composition of any preceding embodiment, wherein:

the fusion polypeptide includes at least one epitope from each of SEQ ID NOs 7, 8 and 9 and, upon administration to a mouse, can elicit antibodies that can recognize all three of: (a) a polypeptide consisting of SEQ ID NO. 4, (b) a polypeptide consisting of SEQ ID NO. 5, (c) a polypeptide consisting of SEQ ID NO. 6;

after administration to a mouse, the NHBA polypeptide can elicit an antibody that can bind to a polypeptide consisting of the amino acid sequence of SEQ ID No. 13;

and/or

After administration to a mouse, the NadA polypeptide can elicit an antibody that can bind to a polypeptide consisting of the amino acid sequence of SEQ ID No. 18.

5. The composition of any preceding embodiment, wherein the fHbp fusion polypeptide has the formula NH₂—A-[-X-L ]₃-B-COOH, wherein each X is a different variant fHbp sequence, L is an optional linker amino acid sequence, a is an optional N-terminal amino acid sequence, and B is an optional C-terminal amino acid sequence.

6. The composition of embodiment 5, wherein the variant fHbp sequence is in the order v2-v3-v1 from N-terminus to C-terminus.

7. The composition of embodiment 6, wherein said fusion polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 10, 29, 30, 31, 32, 33, 34, 35, 36, 37, and 38.

8. The composition of any preceding embodiment, wherein: (a) the fHbp fusion polypeptide has an amino acid sequence of SEQ ID NO 10, SEQ ID NO 36 or SEQ ID NO 38; (b) the NHBA polypeptide comprises an amino acid sequence SEQ ID NO 12; and (c) the NadA polypeptide has the amino acid sequence of SEQ ID NO 19.

9. The composition of any preceding embodiment, wherein the OMV is from a serogroup B strain.

10. The composition of embodiment 9, wherein said OMV is prepared from strain NZ 98/254.

11. The composition of any preceding embodiment, wherein the OMV is present at a concentration of 10 μ g/ml to 15 μ g/ml.

12. The composition of any preceding embodiment, wherein the fHbp, NHBA and NadA polypeptides are present at a concentration of 50-150 μ g/ml.

13. The composition of any preceding embodiment, further comprising an aluminum hydroxide adjuvant.

14. A method for protecting a mammal from meningococcal infection comprising administering to the mammal the immunogenic composition of any preceding embodiment.

15. The method of embodiment 14, wherein the mammal is a human.

Examples

Example 1: BEXSERO vaccine (for reference)

BEXSERO ™ products are safe and effective and have been licensed for human use in Europe and elsewhere. It has the following immunogenic components per 0.5ml dose:

immunogens	Measurement of	Note
			fHbp	50µg	Fusion polypeptide with NMB2091 at the N-terminus
NHBA	50µg	Fusion polypeptide with NMB1030 at C-terminus
			NadA	50µg	-
OMV	25 microgram (Total protein)	Strain NZ98/254 (B:4: P1.7-2,4, L1,3)

These immunogens were adsorbed to an aluminum hydroxide adjuvant (0.5 mg Al per dose)⁺⁺⁺). The composition also includes NaCl, histidine buffer, and sucrose.

Example 2: stabilized and stabilized non-binding fusion polypeptides

The inventors have studied two different types of mutations in v2 and v 3: first, they have identified residues within SEQ ID NO 2 and SEQ ID NO 3 that can be modified to increase the stability of the polypeptide. Second, they have identified residues that reduce binding to human factor h (fh). Mutant fHbp polypeptides comprising two types of mutations have enhanced properties. In particular, fHbp mutants that do not bind factor H, but retain immunogenicity, are advantageous because the resulting antibody response is directed against an epitope in or near the fH binding site. Such epitopes may be masked by factor H binding after vaccination with the wild-type fHbp vaccine antigen. The amino acids of most interest are as follows, numbered according to the full-length sequences (SEQ ID NOS: 2 and 3) and also according to the Δ G sequences (SEQ ID NOS: 8 and 9):

when only one of these residues is mutated, it is preferably leucine.

Mutations for stability and fHbp binding were combined into mutant forms of v2 and v3 and fused to a mutant v1 sequence containing the R41S mutation. The mutants were fused in the sequence v2-v3-v1 and ligated using a linker to give 731 SNB (SEQ ID NO: 38). The fusion polypeptide included a total of 7 point mutations compared to the three wild-type sequences (fig. 2).

The mutations for stability in v2 and v3, respectively, were fused to the ` R41S ` mutant v1 sequence in the order v2-v3-v1 and ligated using a linker to give 731S (SEQ ID NO: 40). Thus, the fusion polypeptide included a total of 5 point mutations compared to the three wild-type sequences (fig. 2).

The ability of non-fH-binding forms of fHbp to elicit SBA titers was tested in transgenic (Tg) mice:

these data indicate that the non-bound form of fHbp may be more immunogenic.

Example 3: substitution of NMB2091-fHbp fusion

The BEXSERO-cell product was modified by replacing the NMB2091-fHbp fusion polypeptide with a "triple fusion" polypeptide of the fHbp variant (where v2-v3-v1 is from N-terminus to C-terminus). The fusion polypeptide has an amino acid sequence of SEQ ID NO 10. In addition, OMV components were removed. The two vaccines were compared in day 0, 21 and 35 immunized mice, where sera were evaluated at day 34 and 49 against a panel of 15 serogroup B strains in various clonal complexes (MLST and ET classification). Antigen was administered at 20 μ g/dose using 3mg/ml adjuvant.

The proportion of strains with SBA titers above the respective thresholds was as follows:

threshold value	Initial vaccine	Modified vaccines
			> 128	100 %	100 %
> 1024	93 %	80 %
			> 4096	53 %	60 %

Thus, at high anti-MenB SBA titers: (>4096) Next, the use of the v2-v3-v1 fusion polypeptide can provide a higher ratio (60%vs. 53%) was added.

Example 4: 4-fold reduction of OMV dose

The BEXSERO product was modified by replacing the NMB2091-fHbp fusion polypeptide with a "triple fusion" fHbp v2-v3-v1 polypeptide (SEQ ID NO:10) and also by (i) 4-fold reduction of OMV dose to 12.5 μ g/ml or (ii) removal of OMV components. Thus, three compositions were prepared:

to evaluate the immunogenicity of these three vaccines, human subjects received three doses at monthly intervals (months 0,1, 2). Sera were taken at months 0,1, 2 and 3, and then 6 months (month 8) after the third dose for evaluation against a panel of related strains. Titers (GMT) were as follows:

pooled patient sera were used to assess coverage of a panel of 7 MenB strains expressing v1 fHbp. A similar number of strains were well covered in each group, but the titer (GMT) in group C was the highest:

	M	C	S
				time zero	<10	<10	<10
3 months old	70	140	40
				8 months old	15	50	10

Individual patient sera were tested against a panel of 6 MenB strains expressing v2 or v3 fHbp (one strain tested twice). Again, the titer (GMT) in group C was highest:

furthermore, the proportion of immunized subjects with SBA titers above 1:8 in group C is generally higher compared to groups M and S, e.g. 80% or higher for strain M1239 after 3 doses compared to 50% or lower for the other two groups.

The RCD curve (reverse cumulative distribution) of SBA titers also shows a better profile, e.g. fig. 1 shows a curve for month 3 serum against strain UK293, with group C being significantly higher than the other groups.

Pooled patient sera were used to assess coverage of a panel of 26 MenB strains expressing v2 or v3 fHbp. Again, the titer (GMT) in group C was highest:

	M	C	S
				3 months old	23	91	25
8 months old	7	43	9

Thus, these data show that vaccine 'C' (in which fHbp immunogen has been replaced and OMV dose reduced by 4-fold) compares favorably with the BEXSERO ­ vaccine. Indeed, both individual subjects and pooled sera showed better seroresponse rates, higher GMT and increased strain coverage for vaccine 'C' when compared to the BEXSERO ­ vaccine.

Example 5: antibody affinity

The avidity (avidity) of antibodies from patients in groups 'C' and 'S' was compared using a Gyrolab-based system comprising a washing step using a chaotrope to dissociate low affinity (affinity) antibodies from the antigen, giving the "avidity index" as a percentage of high affinity anti-v 1.fhbp antibodies in total v1. fhbp-specific antibodies. 20 sera isolates were evaluated 1 month after the first dose and 1 month after the third dose. In addition, SBA titers were evaluated against strain H44/76 and a correlation between affinity index and SBA titer (log2) was determined.

The results (R and p by Pearson correlation) are as follows:

thus, there was a significant correlation between SBA titers and affinity indices at the two time points in group 'C' but not in group 'S'. In subjects receiving vaccines with 12.5 μ g/ml OMVs, the avidity index correlated with SBA titers, indicating that the presence of OMVs had a positive effect on the quality of the induced antibodies. Overall, in subjects receiving OMVs, the trend is that bactericidal titers are higher and they correlate with the avidity of the antibodies induced by the vaccine formulation.

A subset of var2/3 strains was selected for individual subject serum testing based on the following criteria: (i) strains not previously covered by Bexsero in clinical trials, (ii) strains belonging to the relevant clonal complex, (iii) strains expressing epidemiologically related subforms of fHbp (subvariant), (iv) with moderate levels of fHbp expression, (v) strains specifically killed by 741-231 (competitive hSBA). The results are shown in FIGS. 3(a) to 3(g), demonstrating that 741-. Thus, the hSBA test indicated that the preparation comprising the 741-231 fusion was comparable to Bexsero. Indeed, single subject serum and pooled serum analyses of the var2/3 strain showed better serum response rates, higher GMT titers and increased strain coverage for the preparation comprising 741-231+1/4OMV + alum (alum).

Example 6: reduction of OMV dose and use of 731 ' S ' and 731 ' SNB

BEXSERO product was modified by replacing the NMB2091-fHbp fusion polypeptide with a "triple fusion" stabilized or stabilized non-binding fHbp v2-v3-v1 polypeptide (SEQ ID NOS: 40 and 38, respectively) and also by reducing the OMV dose to 10 μ g/ml or 2.5 μ g/ml:

to prepare mouse antisera, 6 week old CD1 female mice (Charles River) were immunized with 20. mu.g of NadA, NHBA-NMB1030 and NMB2091-fHbp, fHbp 231S or fHbp 231SNB with 10. mu.g or 2.5. mu.g of OMV derived from strain NZ 98/254. 8 mice were used per group. The antigen was administered intraperitoneally with aluminum hydroxide (3 mg/ml) on days 0, 21 and 35. Sera were collected 2 weeks after the last bleed and heat inactivated at 56 ℃ for 30 minutes prior to testing.

Serum bactericidal assay with animal serum and human complement

Serum bactericidal activity against Nm strains was assessed as described previously. Human serum or plasma from healthy adults (with no intrinsic bactericidal activity when tested at 25 or 50% final concentration) was used as a complement source. Serum bactericidal titer was defined as the dilution of serum that resulted in a 50% reduction in Colony Forming Units (CFU) per ml after 60 minutes of incubation of the bacteria with the reaction mixture compared to control CFU per ml at time 0.

The lowest dilution tested for each serum was 1:16 (detection limit). For analysis purposes, titers below the detection limit were set at half this limit, and the positive threshold was defined as a 4-fold increase compared to this value (i.e., 32). Pooled sera from mice immunized with the Bexsero preparation were below the positive threshold for 14 of the 34 strains tested, while pooled sera from the second generation preparation were below the detection limit for only 1 strain in the case of the vaccine preparation containing fHbp 231SNB and below the detection limit for 1 strain in the case of the preparation containing fHbp 231S.

The hSBA data reported in the table below show that among a group of 34 strains tested, vaccine formulations containing fHbp 231S or fHbp 231SNB elicited an increase in coverage compared to Bexsero:

it will be understood that the invention has been described above by way of example only and that modifications may be made whilst remaining within the scope and spirit of the invention.

Reference to the literature

[1] Carter (2013) BioDrugs 27:263-74.

[2] WO99/57280.

[3]Masignani et al (2003)J Exp Med 197:789-799.

[4]Welsch et al (2004)J Immunol 172:5605-15.

[5]Hou et al (2005)J Infect Dis 192(4):580-90.

[6] WO03/063766.

[7]Fletcher et al (2004)Infect Immun 72:2088-2100.

[8]Zhu et al (2005)Infect Immun 73(10):6838-45.

[9]Cendron et al (2011)Acta Crystallogr Sect F Struct Biol Cryst Commun. 67:531-5.

[10]Mascioni et al (2009)J Biol Chem 284:8738-46.

[11]Pizza et al (2008)Vaccine 26 Suppl 8:I46-8.

[12]Malito et al (2013)PNAS USA 110:3304-9.

[13]Marshall et al (2012)Pediatr Infect Dis J 31:1061-8.

[14]McNeil et al (2013)Microbiol Mol Biol Rev 77:234-52.

[15]Serrruto et al (2012)Vaccine 30 Suppl 2: B87-97.

[16]Scarselli et al (2011)Sci Transl Med 3:91ra62.

[17]Beernik et al (2008)Infect Immun 76:4232-40.

[18]Scarselli et al (2009)J Mol Biol 386:97-108.

[19]Giuntini et al (2012)PLoS One 7:e34272.

[20]Vu et al (2012)Sci Rep 2:341.

[21]Faleri et al (2013)FASEB J fj.13-239012.

[22]Beernik et al (2011)J Immunol 186:3606-14.

[23]Tettelin et al (2000)Science 287:1809-1815.

[24] WO00/66741.

[25] WO02/09643.

[26]Katial et al (2002)Infect Immun 70:702-707.

[27] WO01/52885.

[28] European patent 0301992.

[29]Frasch et al (2001)Methods in Molecular MedicineChapter 7 ('of volume 66)'Meningococcal Vaccines: Methods and Protocols’Edit Pollard& Maiden).

[30]Bjune et al (1991)Lancet 338(8775):1093-1096.

[31]Fukasawa et al (1999)Vaccine 17:2951-2958.

[32] WO02/09746.

[33]Rosenqvist et al (1998)Dev. Biol. Stand. 92:323-333.

[34] European patent 0011243.

[35]Fredriksen et al (1991)NIPH Ann. 14(2):67-80.

[36] WO01/91788.

[37] WO2004/019977.

[38] Us patent 6,558,677.

[39] WO01/09350.

[40] European patent 0449958.

[41] EP-A-0996712.

[42] EP-A-0680512.

[43] WO02/062378.

[44] WO99/59625.

[45] Us patent 6,180,111.

[46] WO01/34642.

[47]Peeters et al (1996)Vaccine 14:1008-1015.

[48]Vermont et al (2003)Infect Immun 71:1650-1655.

[49] WO2004/014417.

[50] WO2005/004908.

[51] WO2011/036562.

[52]Pizza et al (2000)Science 287:1816-1820.

[53] WO2007/028408.

[54] http://pubmlst.org/ neisseria/

[55]Budroni et al (2011)PNAS USA 108:4494-99.

[56]Goldschneider et al (1969)J. Exp. Med. 129:1307-26.

[57]Santos et al (2001)Clinical and Diagnostic Laboratory Immunology 8:616-23.

[58]Frasch et al (2009)Vaccine 27S:B112-6.

[59] Gennaro (2000) Remington: The Science and Practice of Pharmacy.20 th edition, ISBN: 0683306472.

[60] WO03/009869.

[61] Vaccine Design…(1995) Editing Powell& Newman. ISBN: 030644867X. Plenum.

[62]Giuliani et al (2006)Proc Natl Acad Sci U S A. 103:10834-9.

[63] WO2004/032958.

[64]Costantino et al (1992)Vaccine 10:691-698.

[65] Costantino et al (1999)Vaccine 17:1251-1263.

[66] WO03/007985.

[67] Watson (2000) Pediatr Infect Dis J 19:331-332.

[68] Rubin (2000) Pediatr Clin North Am 47:269-285, v.

[69] Jedrzejas (2001) Microbiol Mol Biol Rev 65:187-207.

[70] Bell (2000) Pediatr Infect Dis J 19:1187-1188.

[71] Iwarson (1995) APMIS 103:321-326.

[72]Gerlich et al (1990)Vaccine 8 Suppl:S63-68 & 79-80.

[73] Vaccines (1988) Editing Plotkin& Mortimer. ISBN 0-7216-1946-0.

[74]Del Guidiate et al (1998)Molecular Aspects of Medicine 19:1-70.

[75]Gustafsson et al (1996)N. Engl. J. Med. 334:349-355.

[76]Rappuoli et al (1991)TIBTECH 9:232-238.

[77]Sutter et al (2000)Pediatr Clin North Am 47:287-308.

[78] Zimmerman & Spann (1999) Am Fam Physician 59:113-118, 125-126.

[79] McMichael (2000) Vaccine 19 Suppl 1:S101-107.

[80] Schuchat (1999) Lancet 353(9146):51-6.

[81] WO02/34771.

[82] Dale (1999) Infect Dis Clin North Am 13:227-43, viii.

[83]Ferretti et al (2001)PNAS USA 98: 4658-4663.

[84]Kuroda et al (2001)Lancet 357(9264), 1225 and 1240, see page 1218 and 1219.

[85] Jones (2001) Curr Opin Investig Drugs 2:47-49.

[86]Ravenscroft et al (1999)Vaccine 17:2802-2816.

[87] Research Disclosure, 453077 (Jan 2002).

[88] EP-A-0372501.

[89] EP-A-0378881.

[90] EP-A-0427347.

[91] WO93/17712.

[92] WO94/03208.

[93] WO98/58668.

[94] EP-A-0471177.

[95] WO91/01146.

[96]Falugi et al (2001)Eur J Immunol 31:3816-3824.

[97]Baraldo et al (2004)Infect Immun 72(8):4884-7.

[98] EP-A-0594610.

[99]Ruan et al (1990)J Immunol 145:3379-3384.

[100] WO00/56360.

[101]Kuo et al (1995)Infect Immun 63:2706-13.

[102]Michon et al (1998)Vaccine. 16:1732-41.

[103] WO02/091998.

[104] WO01/72337.

[105] WO00/61761.

[106] WO00/33882

[107]Lees et al (1996)Vaccine 14:190-198.

[108] WO95/08348.

[109] U.S. Pat. No. 4,882,317

[110] U.S. Pat. No. 4,695,624

[111]Porro et al (1985)Mol Immunol 22:907-919.s

[112] EP-A-0208375

[113] WO00/10599

[114] Gever et al Med. Microbiol. Immunol, 165: 171-.

[115] Us patent 4,057,685.

[116] U.S. Pat. Nos. 4,673,574, 4,761,283, 4,808,700.

[117] U.S. Pat. No. 4,459,286.

[118] U.S. Pat. No. 4,965,338

[119] Us patent 4,663,160.

[120] U.S. Pat. No. 4,761,283

[121] U.S. Pat. No. 4,356,170

[122] Needleman & Wunsch (1970) J. Mol. Biol. 48, 443-453.

[123]Rice et al (2000)Trends Genet 16:276-277.

Sequence listing

<110> GLAXOSMITHKLINE BIOLOGICALS S.A.

<120> meningococcal vaccine

<130> VN56308 WO

<140>

<141>

<150> EP 14177563.5

<151> 2014-07-17

<160> 44

<170> PatentIn version 3.5

<210> 1

<211> 274

<212> PRT

<213> Neisseria meningitidis

<400> 1

Met Asn Arg Thr Ala Phe Cys Cys Leu Ser Leu Thr Thr Ala Leu Ile

1 5 10 15

Leu Thr Ala Cys Ser Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly

20 25 30

Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys

35 40 45

Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys

50 55 60

Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp

65 70 75 80

Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp

85 90 95

Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser

100 105 110

Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe

115 120 125

Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala

130 135 140

Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His Thr Ser Phe

145 150 155 160

Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly Thr Ala Phe

165 170 175

Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Ala

180 185 190

Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu

195 200 205

Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly Lys Arg His

210 215 220

Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu Lys Gly Ser

225 230 235 240

Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val Ala Gly Ser

245 250 255

Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala

260 265 270

Lys Gln

<210> 2

<211> 273

<212> PRT

<213> Neisseria meningitidis

<400> 2

Met Asn Arg Thr Ala Phe Cys Cys Leu Ser Leu Thr Ala Ala Leu Ile

1 5 10 15

Leu Thr Ala Cys Ser Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly

20 25 30

Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys

35 40 45

Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys

50 55 60

Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp

65 70 75 80

Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp

85 90 95

Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser

100 105 110

Gly Glu Phe Gln Ile Tyr Lys Gln Asp His Ser Ala Val Val Ala Leu

115 120 125

Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys Ile Asp Ser Leu Ile Asn

130 135 140

Gln Arg Ser Phe Leu Val Ser Gly Leu Gly Gly Glu His Thr Ala Phe

145 150 155 160

Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr His Gly Lys Ala Phe Ser

165 170 175

Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Ala Ala

180 185 190

Lys Gln Gly His Gly Lys Ile Glu His Leu Lys Thr Pro Glu Gln Asn

195 200 205

Val Glu Leu Ala Ala Ala Glu Leu Lys Ala Asp Glu Lys Ser His Ala

210 215 220

Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser Glu Glu Lys Gly Thr Tyr

225 230 235 240

His Leu Ala Leu Phe Gly Asp Arg Ala Gln Glu Ile Ala Gly Ser Ala

245 250 255

Thr Val Lys Ile Gly Glu Lys Val His Glu Ile Gly Ile Ala Gly Lys

260 265 270

Gln

<210> 3

<211> 281

<212> PRT

<213> Neisseria meningitidis

<400> 3

Met Asn Arg Thr Ala Phe Cys Cys Leu Ser Leu Thr Thr Ala Leu Ile

1 5 10 15

Leu Thr Ala Cys Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Val

20 25 30

Ala Ala Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu

35 40 45

Asp His Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile

50 55 60

Pro Gln Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr

65 70 75 80

Phe Lys Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys

85 90 95

Asn Asp Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp

100 105 110

Gly Gln Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln

115 120 125

Asn His Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro

130 135 140

Asp Lys Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly

145 150 155 160

Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala

165 170 175

Glu Tyr His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu

180 185 190

His Tyr Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu

195 200 205

His Leu Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu

210 215 220

Lys Ala Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr

225 230 235 240

Gly Ser Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg

245 250 255

Ala Gln Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val

260 265 270

His Glu Ile Gly Ile Ala Gly Lys Gln

275 280

<210> 4

<211> 255

<212> PRT

<213> Neisseria meningitidis

<400> 4

Cys Ser Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Ala Gly Leu

1 5 10 15

Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Gly Leu Gln

20 25 30

Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys Leu Lys Leu

35 40 45

Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp Ser Leu Asn

50 55 60

Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp Phe Ile Arg

65 70 75 80

Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser Gly Glu Phe

85 90 95

Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe Gln Thr Glu

100 105 110

Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala Lys Arg Gln

115 120 125

Phe Arg Ile Gly Asp Ile Ala Gly Glu His Thr Ser Phe Asp Lys Leu

130 135 140

Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly Thr Ala Phe Gly Ser Asp

145 150 155 160

Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Ala Ala Lys Gln

165 170 175

Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu Asn Val Asp

180 185 190

Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly Lys Arg His Ala Val Ile

195 200 205

Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu Lys Gly Ser Tyr Ser Leu

210 215 220

Gly Ile Phe Gly Gly Lys Ala Gln Glu Val Ala Gly Ser Ala Glu Val

225 230 235 240

Lys Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala Lys Gln

245 250 255

<210> 5

<211> 254

<212> PRT

<213> Neisseria meningitidis

<400> 5

Cys Ser Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Ala Gly Leu

1 5 10 15

Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Ser Leu Gln

20 25 30

Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys Leu Lys Leu

35 40 45

Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp Ser Leu Asn

50 55 60

Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp Phe Ile Arg

65 70 75 80

Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser Gly Glu Phe

85 90 95

Gln Ile Tyr Lys Gln Asp His Ser Ala Val Val Ala Leu Gln Ile Glu

100 105 110

Lys Ile Asn Asn Pro Asp Lys Ile Asp Ser Leu Ile Asn Gln Arg Ser

115 120 125

Phe Leu Val Ser Gly Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu

130 135 140

Pro Asp Gly Lys Ala Glu Tyr His Gly Lys Ala Phe Ser Ser Asp Asp

145 150 155 160

Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly

165 170 175

His Gly Lys Ile Glu His Leu Lys Thr Pro Glu Gln Asn Val Glu Leu

180 185 190

Ala Ala Ala Glu Leu Lys Ala Asp Glu Lys Ser His Ala Val Ile Leu

195 200 205

Gly Asp Thr Arg Tyr Gly Ser Glu Glu Lys Gly Thr Tyr His Leu Ala

210 215 220

Leu Phe Gly Asp Arg Ala Gln Glu Ile Ala Gly Ser Ala Thr Val Lys

225 230 235 240

Ile Gly Glu Lys Val His Glu Ile Gly Ile Ala Gly Lys Gln

245 250

<210> 6

<211> 262

<212> PRT

<213> Neisseria meningitidis

<400> 6

Cys Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Val Ala Ala Asp

1 5 10 15

Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys

20 25 30

Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile Pro Gln Asn

35 40 45

Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys Ala

50 55 60

Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys

65 70 75 80

Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln Thr

85 90 95

Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His Ser

100 105 110

Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys Thr

115 120 125

Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly Gly

130 135 140

Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr His

145 150 155 160

Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr Ser

165 170 175

Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu Lys

180 185 190

Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala Asp

195 200 205

Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser Glu

210 215 220

Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln Glu

225 230 235 240

Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu Ile

245 250 255

Gly Ile Ala Gly Lys Gln

260

<210> 7

<211> 248

<212> PRT

<213> Neisseria meningitidis

<400> 7

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His

85 90 95

Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His

100 105 110

Ser Gly Lys Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala

115 120 125

Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr

130 135 140

Tyr Arg Gly Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr

145 150 155 160

Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His

165 170 175

Leu Lys Ser Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys

180 185 190

Pro Asp Gly Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn

195 200 205

Gln Ala Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala

210 215 220

Gln Glu Val Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg

225 230 235 240

His Ile Gly Leu Ala Ala Lys Gln

245

<210> 8

<211> 247

<212> PRT

<213> Neisseria meningitidis

<400> 8

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln

245

<210> 9

<211> 250

<212> PRT

<213> Neisseria meningitidis

<400> 9

Val Ala Ala Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser

20 25 30

Ile Pro Gln Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys

35 40 45

Thr Phe Lys Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu

50 55 60

Lys Asn Asp Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val

65 70 75 80

Asp Gly Gln Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys

85 90 95

Gln Asn His Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn

100 105 110

Pro Asp Lys Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser

115 120 125

Gly Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys

130 135 140

Ala Glu Tyr His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg

145 150 155 160

Leu His Tyr Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile

165 170 175

Glu His Leu Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu

180 185 190

Leu Lys Ala Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg

195 200 205

Tyr Gly Ser Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp

210 215 220

Arg Ala Gln Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys

225 230 235 240

Val His Glu Ile Gly Ile Ala Gly Lys Gln

245 250

<210> 10

<211> 776

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 10

Met Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg Val Ala Ala Asp

1 5 10 15

Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys

20 25 30

Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn

35 40 45

Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn

50 55 60

Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg

65 70 75 80

Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu

85 90 95

Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His Ser Ala Val Val

100 105 110

Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys Ile Asp Ser Leu

115 120 125

Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly Gly Glu His Thr

130 135 140

Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr His Gly Lys Ala

145 150 155 160

Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe

165 170 175

Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu Lys Thr Pro Glu

180 185 190

Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala Asp Glu Lys Ser

195 200 205

His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser Glu Glu Lys Gly

210 215 220

Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln Glu Ile Ala Gly

225 230 235 240

Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu Ile Gly Ile Ala

245 250 255

Gly Lys Gln Gly Ser Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg

260 265 270

Val Ala Ala Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro

275 280 285

Leu Asp His Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser

290 295 300

Ile Pro Gln Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys

305 310 315 320

Thr Phe Lys Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu

325 330 335

Lys Asn Asp Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val

340 345 350

Asp Gly Gln Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys

355 360 365

Gln Asn His Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn

370 375 380

Pro Asp Lys Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser

385 390 395 400

Gly Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys

405 410 415

Ala Glu Tyr His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg

420 425 430

Leu His Tyr Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile

435 440 445

Glu His Leu Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu

450 455 460

Leu Lys Ala Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg

465 470 475 480

Tyr Gly Ser Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp

485 490 495

Arg Ala Gln Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys

500 505 510

Val His Glu Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly

515 520 525

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

530 535 540

Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser

545 550 555 560

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

565 570 575

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

580 585 590

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

595 600 605

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His

610 615 620

Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His

625 630 635 640

Ser Gly Lys Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala

645 650 655

Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr

660 665 670

Tyr Arg Gly Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr

675 680 685

Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His

690 695 700

Leu Lys Ser Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys

705 710 715 720

Pro Asp Gly Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn

725 730 735

Gln Ala Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala

740 745 750

Gln Glu Val Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg

755 760 765

His Ile Gly Leu Ala Ala Lys Gln

770 775

<210> 11

<211> 488

<212> PRT

<213> Neisseria meningitidis

<400> 11

Met Phe Lys Arg Ser Val Ile Ala Met Ala Cys Ile Phe Ala Leu Ser

1 5 10 15

Ala Cys Gly Gly Gly Gly Gly Gly Ser Pro Asp Val Lys Ser Ala Asp

20 25 30

Thr Leu Ser Lys Pro Ala Ala Pro Val Val Ser Glu Lys Glu Thr Glu

35 40 45

Ala Lys Glu Asp Ala Pro Gln Ala Gly Ser Gln Gly Gln Gly Ala Pro

50 55 60

Ser Ala Gln Gly Ser Gln Asp Met Ala Ala Val Ser Glu Glu Asn Thr

65 70 75 80

Gly Asn Gly Gly Ala Val Thr Ala Asp Asn Pro Lys Asn Glu Asp Glu

85 90 95

Val Ala Gln Asn Asp Met Pro Gln Asn Ala Ala Gly Thr Asp Ser Ser

100 105 110

Thr Pro Asn His Thr Pro Asp Pro Asn Met Leu Ala Gly Asn Met Glu

115 120 125

Asn Gln Ala Thr Asp Ala Gly Glu Ser Ser Gln Pro Ala Asn Gln Pro

130 135 140

Asp Met Ala Asn Ala Ala Asp Gly Met Gln Gly Asp Asp Pro Ser Ala

145 150 155 160

Gly Gly Gln Asn Ala Gly Asn Thr Ala Ala Gln Gly Ala Asn Gln Ala

165 170 175

Gly Asn Asn Gln Ala Ala Gly Ser Ser Asp Pro Ile Pro Ala Ser Asn

180 185 190

Pro Ala Pro Ala Asn Gly Gly Ser Asn Phe Gly Arg Val Asp Leu Ala

195 200 205

Asn Gly Val Leu Ile Asp Gly Pro Ser Gln Asn Ile Thr Leu Thr His

210 215 220

Cys Lys Gly Asp Ser Cys Ser Gly Asn Asn Phe Leu Asp Glu Glu Val

225 230 235 240

Gln Leu Lys Ser Glu Phe Glu Lys Leu Ser Asp Ala Asp Lys Ile Ser

245 250 255

Asn Tyr Lys Lys Asp Gly Lys Asn Asp Lys Phe Val Gly Leu Val Ala

260 265 270

Asp Ser Val Gln Met Lys Gly Ile Asn Gln Tyr Ile Ile Phe Tyr Lys

275 280 285

Pro Lys Pro Thr Ser Phe Ala Arg Phe Arg Arg Ser Ala Arg Ser Arg

290 295 300

Arg Ser Leu Pro Ala Glu Met Pro Leu Ile Pro Val Asn Gln Ala Asp

305 310 315 320

Thr Leu Ile Val Asp Gly Glu Ala Val Ser Leu Thr Gly His Ser Gly

325 330 335

Asn Ile Phe Ala Pro Glu Gly Asn Tyr Arg Tyr Leu Thr Tyr Gly Ala

340 345 350

Glu Lys Leu Pro Gly Gly Ser Tyr Ala Leu Arg Val Gln Gly Glu Pro

355 360 365

Ala Lys Gly Glu Met Leu Ala Gly Ala Ala Val Tyr Asn Gly Glu Val

370 375 380

Leu His Phe His Thr Glu Asn Gly Arg Pro Tyr Pro Thr Arg Gly Arg

385 390 395 400

Phe Ala Ala Lys Val Asp Phe Gly Ser Lys Ser Val Asp Gly Ile Ile

405 410 415

Asp Ser Gly Asp Asp Leu His Met Gly Thr Gln Lys Phe Lys Ala Ala

420 425 430

Ile Asp Gly Asn Gly Phe Lys Gly Thr Trp Thr Glu Asn Gly Ser Gly

435 440 445

Asp Val Ser Gly Lys Phe Tyr Gly Pro Ala Gly Glu Glu Val Ala Gly

450 455 460

Lys Tyr Ser Tyr Arg Pro Thr Asp Ala Glu Lys Gly Gly Phe Gly Val

465 470 475 480

Phe Ala Gly Lys Lys Glu Gln Asp

485

<210> 12

<211> 464

<212> PRT

<213> Neisseria meningitidis

<400> 12

Ser Pro Asp Val Lys Ser Ala Asp Thr Leu Ser Lys Pro Ala Ala Pro

1 5 10 15

Val Val Ser Glu Lys Glu Thr Glu Ala Lys Glu Asp Ala Pro Gln Ala

20 25 30

Gly Ser Gln Gly Gln Gly Ala Pro Ser Ala Gln Gly Ser Gln Asp Met

35 40 45

Ala Ala Val Ser Glu Glu Asn Thr Gly Asn Gly Gly Ala Val Thr Ala

50 55 60

Asp Asn Pro Lys Asn Glu Asp Glu Val Ala Gln Asn Asp Met Pro Gln

65 70 75 80

Asn Ala Ala Gly Thr Asp Ser Ser Thr Pro Asn His Thr Pro Asp Pro

85 90 95

Asn Met Leu Ala Gly Asn Met Glu Asn Gln Ala Thr Asp Ala Gly Glu

100 105 110

Ser Ser Gln Pro Ala Asn Gln Pro Asp Met Ala Asn Ala Ala Asp Gly

115 120 125

Met Gln Gly Asp Asp Pro Ser Ala Gly Gly Gln Asn Ala Gly Asn Thr

130 135 140

Ala Ala Gln Gly Ala Asn Gln Ala Gly Asn Asn Gln Ala Ala Gly Ser

145 150 155 160

Ser Asp Pro Ile Pro Ala Ser Asn Pro Ala Pro Ala Asn Gly Gly Ser

165 170 175

Asn Phe Gly Arg Val Asp Leu Ala Asn Gly Val Leu Ile Asp Gly Pro

180 185 190

Ser Gln Asn Ile Thr Leu Thr His Cys Lys Gly Asp Ser Cys Ser Gly

195 200 205

Asn Asn Phe Leu Asp Glu Glu Val Gln Leu Lys Ser Glu Phe Glu Lys

210 215 220

Leu Ser Asp Ala Asp Lys Ile Ser Asn Tyr Lys Lys Asp Gly Lys Asn

225 230 235 240

Asp Lys Phe Val Gly Leu Val Ala Asp Ser Val Gln Met Lys Gly Ile

245 250 255

Asn Gln Tyr Ile Ile Phe Tyr Lys Pro Lys Pro Thr Ser Phe Ala Arg

260 265 270

Phe Arg Arg Ser Ala Arg Ser Arg Arg Ser Leu Pro Ala Glu Met Pro

275 280 285

Leu Ile Pro Val Asn Gln Ala Asp Thr Leu Ile Val Asp Gly Glu Ala

290 295 300

Val Ser Leu Thr Gly His Ser Gly Asn Ile Phe Ala Pro Glu Gly Asn

305 310 315 320

Tyr Arg Tyr Leu Thr Tyr Gly Ala Glu Lys Leu Pro Gly Gly Ser Tyr

325 330 335

Ala Leu Arg Val Gln Gly Glu Pro Ala Lys Gly Glu Met Leu Ala Gly

340 345 350

Ala Ala Val Tyr Asn Gly Glu Val Leu His Phe His Thr Glu Asn Gly

355 360 365

Arg Pro Tyr Pro Thr Arg Gly Arg Phe Ala Ala Lys Val Asp Phe Gly

370 375 380

Ser Lys Ser Val Asp Gly Ile Ile Asp Ser Gly Asp Asp Leu His Met

385 390 395 400

Gly Thr Gln Lys Phe Lys Ala Ala Ile Asp Gly Asn Gly Phe Lys Gly

405 410 415

Thr Trp Thr Glu Asn Gly Ser Gly Asp Val Ser Gly Lys Phe Tyr Gly

420 425 430

Pro Ala Gly Glu Glu Val Ala Gly Lys Tyr Ser Tyr Arg Pro Thr Asp

435 440 445

Ala Glu Lys Gly Gly Phe Gly Val Phe Ala Gly Lys Lys Glu Gln Asp

450 455 460

<210> 13

<211> 471

<212> PRT

<213> Neisseria meningitidis

<400> 13

Cys Gly Gly Gly Gly Gly Gly Ser Pro Asp Val Lys Ser Ala Asp Thr

1 5 10 15

Leu Ser Lys Pro Ala Ala Pro Val Val Ser Glu Lys Glu Thr Glu Ala

20 25 30

Lys Glu Asp Ala Pro Gln Ala Gly Ser Gln Gly Gln Gly Ala Pro Ser

35 40 45

Ala Gln Gly Ser Gln Asp Met Ala Ala Val Ser Glu Glu Asn Thr Gly

50 55 60

Asn Gly Gly Ala Val Thr Ala Asp Asn Pro Lys Asn Glu Asp Glu Val

65 70 75 80

Ala Gln Asn Asp Met Pro Gln Asn Ala Ala Gly Thr Asp Ser Ser Thr

85 90 95

Pro Asn His Thr Pro Asp Pro Asn Met Leu Ala Gly Asn Met Glu Asn

100 105 110

Gln Ala Thr Asp Ala Gly Glu Ser Ser Gln Pro Ala Asn Gln Pro Asp

115 120 125

Met Ala Asn Ala Ala Asp Gly Met Gln Gly Asp Asp Pro Ser Ala Gly

130 135 140

Gly Gln Asn Ala Gly Asn Thr Ala Ala Gln Gly Ala Asn Gln Ala Gly

145 150 155 160

Asn Asn Gln Ala Ala Gly Ser Ser Asp Pro Ile Pro Ala Ser Asn Pro

165 170 175

Ala Pro Ala Asn Gly Gly Ser Asn Phe Gly Arg Val Asp Leu Ala Asn

180 185 190

Gly Val Leu Ile Asp Gly Pro Ser Gln Asn Ile Thr Leu Thr His Cys

195 200 205

Lys Gly Asp Ser Cys Ser Gly Asn Asn Phe Leu Asp Glu Glu Val Gln

210 215 220

Leu Lys Ser Glu Phe Glu Lys Leu Ser Asp Ala Asp Lys Ile Ser Asn

225 230 235 240

Tyr Lys Lys Asp Gly Lys Asn Asp Lys Phe Val Gly Leu Val Ala Asp

245 250 255

Ser Val Gln Met Lys Gly Ile Asn Gln Tyr Ile Ile Phe Tyr Lys Pro

260 265 270

Lys Pro Thr Ser Phe Ala Arg Phe Arg Arg Ser Ala Arg Ser Arg Arg

275 280 285

Ser Leu Pro Ala Glu Met Pro Leu Ile Pro Val Asn Gln Ala Asp Thr

290 295 300

Leu Ile Val Asp Gly Glu Ala Val Ser Leu Thr Gly His Ser Gly Asn

305 310 315 320

Ile Phe Ala Pro Glu Gly Asn Tyr Arg Tyr Leu Thr Tyr Gly Ala Glu

325 330 335

Lys Leu Pro Gly Gly Ser Tyr Ala Leu Arg Val Gln Gly Glu Pro Ala

340 345 350

Lys Gly Glu Met Leu Ala Gly Ala Ala Val Tyr Asn Gly Glu Val Leu

355 360 365

His Phe His Thr Glu Asn Gly Arg Pro Tyr Pro Thr Arg Gly Arg Phe

370 375 380

Ala Ala Lys Val Asp Phe Gly Ser Lys Ser Val Asp Gly Ile Ile Asp

385 390 395 400

Ser Gly Asp Asp Leu His Met Gly Thr Gln Lys Phe Lys Ala Ala Ile

405 410 415

Asp Gly Asn Gly Phe Lys Gly Thr Trp Thr Glu Asn Gly Ser Gly Asp

420 425 430

Val Ser Gly Lys Phe Tyr Gly Pro Ala Gly Glu Glu Val Ala Gly Lys

435 440 445

Tyr Ser Tyr Arg Pro Thr Asp Ala Glu Lys Gly Gly Phe Gly Val Phe

450 455 460

Ala Gly Lys Lys Glu Gln Asp

465 470

<210> 14

<211> 187

<212> PRT

<213> Neisseria meningitidis

<400> 14

Met Lys Lys Ile Ile Phe Ala Ala Leu Ala Ala Ala Ala Ile Ser Thr

1 5 10 15

Ala Ser Ala Ala Thr Tyr Lys Val Asp Glu Tyr His Ala Asn Ala Arg

20 25 30

Phe Ala Ile Asp His Phe Asn Thr Ser Thr Asn Val Gly Gly Phe Tyr

35 40 45

Gly Leu Thr Gly Ser Val Glu Phe Asp Gln Ala Lys Arg Asp Gly Lys

50 55 60

Ile Asp Ile Thr Ile Pro Ile Ala Asn Leu Gln Ser Gly Ser Gln His

65 70 75 80

Phe Thr Asp His Leu Lys Ser Ala Asp Ile Phe Asp Ala Ala Gln Tyr

85 90 95

Pro Asp Ile Arg Phe Val Ser Thr Lys Phe Asn Phe Asn Gly Lys Lys

100 105 110

Leu Val Ser Val Asp Gly Asn Leu Thr Met His Gly Lys Thr Ala Pro

115 120 125

Val Lys Leu Lys Ala Glu Lys Phe Asn Cys Tyr Gln Ser Pro Met Glu

130 135 140

Lys Thr Glu Val Cys Gly Gly Asp Phe Ser Thr Thr Ile Asp Arg Thr

145 150 155 160

Lys Trp Gly Met Asp Tyr Leu Val Asn Val Gly Met Thr Lys Ser Val

165 170 175

Arg Ile Asp Ile Gln Ile Glu Ala Ala Lys Gln

180 185

<210> 15

<211> 168

<212> PRT

<213> Neisseria meningitidis

<400> 15

Ala Thr Tyr Lys Val Asp Glu Tyr His Ala Asn Ala Arg Phe Ala Ile

1 5 10 15

Asp His Phe Asn Thr Ser Thr Asn Val Gly Gly Phe Tyr Gly Leu Thr

20 25 30

Gly Ser Val Glu Phe Asp Gln Ala Lys Arg Asp Gly Lys Ile Asp Ile

35 40 45

Thr Ile Pro Ile Ala Asn Leu Gln Ser Gly Ser Gln His Phe Thr Asp

50 55 60

His Leu Lys Ser Ala Asp Ile Phe Asp Ala Ala Gln Tyr Pro Asp Ile

65 70 75 80

Arg Phe Val Ser Thr Lys Phe Asn Phe Asn Gly Lys Lys Leu Val Ser

85 90 95

Val Asp Gly Asn Leu Thr Met His Gly Lys Thr Ala Pro Val Lys Leu

100 105 110

Lys Ala Glu Lys Phe Asn Cys Tyr Gln Ser Pro Met Glu Lys Thr Glu

115 120 125

Val Cys Gly Gly Asp Phe Ser Thr Thr Ile Asp Arg Thr Lys Trp Gly

130 135 140

Met Asp Tyr Leu Val Asn Val Gly Met Thr Lys Ser Val Arg Ile Asp

145 150 155 160

Ile Gln Ile Glu Ala Ala Lys Gln

165

<210> 16

<211> 644

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 16

Met Ala Ser Pro Asp Val Lys Ser Ala Asp Thr Leu Ser Lys Pro Ala

1 5 10 15

Ala Pro Val Val Ser Glu Lys Glu Thr Glu Ala Lys Glu Asp Ala Pro

20 25 30

Gln Ala Gly Ser Gln Gly Gln Gly Ala Pro Ser Ala Gln Gly Gly Gln

35 40 45

Asp Met Ala Ala Val Ser Glu Glu Asn Thr Gly Asn Gly Gly Ala Ala

50 55 60

Ala Thr Asp Lys Pro Lys Asn Glu Asp Glu Gly Ala Gln Asn Asp Met

65 70 75 80

Pro Gln Asn Ala Ala Asp Thr Asp Ser Leu Thr Pro Asn His Thr Pro

85 90 95

Ala Ser Asn Met Pro Ala Gly Asn Met Glu Asn Gln Ala Pro Asp Ala

100 105 110

Gly Glu Ser Glu Gln Pro Ala Asn Gln Pro Asp Met Ala Asn Thr Ala

115 120 125

Asp Gly Met Gln Gly Asp Asp Pro Ser Ala Gly Gly Glu Asn Ala Gly

130 135 140

Asn Thr Ala Ala Gln Gly Thr Asn Gln Ala Glu Asn Asn Gln Thr Ala

145 150 155 160

Gly Ser Gln Asn Pro Ala Ser Ser Thr Asn Pro Ser Ala Thr Asn Ser

165 170 175

Gly Gly Asp Phe Gly Arg Thr Asn Val Gly Asn Ser Val Val Ile Asp

180 185 190

Gly Pro Ser Gln Asn Ile Thr Leu Thr His Cys Lys Gly Asp Ser Cys

195 200 205

Ser Gly Asn Asn Phe Leu Asp Glu Glu Val Gln Leu Lys Ser Glu Phe

210 215 220

Glu Lys Leu Ser Asp Ala Asp Lys Ile Ser Asn Tyr Lys Lys Asp Gly

225 230 235 240

Lys Asn Asp Gly Lys Asn Asp Lys Phe Val Gly Leu Val Ala Asp Ser

245 250 255

Val Gln Met Lys Gly Ile Asn Gln Tyr Ile Ile Phe Tyr Lys Pro Lys

260 265 270

Pro Thr Ser Phe Ala Arg Phe Arg Arg Ser Ala Arg Ser Arg Arg Ser

275 280 285

Leu Pro Ala Glu Met Pro Leu Ile Pro Val Asn Gln Ala Asp Thr Leu

290 295 300

Ile Val Asp Gly Glu Ala Val Ser Leu Thr Gly His Ser Gly Asn Ile

305 310 315 320

Phe Ala Pro Glu Gly Asn Tyr Arg Tyr Leu Thr Tyr Gly Ala Glu Lys

325 330 335

Leu Pro Gly Gly Ser Tyr Ala Leu Arg Val Gln Gly Glu Pro Ser Lys

340 345 350

Gly Glu Met Leu Ala Gly Thr Ala Val Tyr Asn Gly Glu Val Leu His

355 360 365

Phe His Thr Glu Asn Gly Arg Pro Ser Pro Ser Arg Gly Arg Phe Ala

370 375 380

Ala Lys Val Asp Phe Gly Ser Lys Ser Val Asp Gly Ile Ile Asp Ser

385 390 395 400

Gly Asp Gly Leu His Met Gly Thr Gln Lys Phe Lys Ala Ala Ile Asp

405 410 415

Gly Asn Gly Phe Lys Gly Thr Trp Thr Glu Asn Gly Gly Gly Asp Val

420 425 430

Ser Gly Lys Phe Tyr Gly Pro Ala Gly Glu Glu Val Ala Gly Lys Tyr

435 440 445

Ser Tyr Arg Pro Thr Asp Ala Glu Lys Gly Gly Phe Gly Val Phe Ala

450 455 460

Gly Lys Lys Glu Gln Asp Gly Ser Gly Gly Gly Gly Ala Thr Tyr Lys

465 470 475 480

Val Asp Glu Tyr His Ala Asn Ala Arg Phe Ala Ile Asp His Phe Asn

485 490 495

Thr Ser Thr Asn Val Gly Gly Phe Tyr Gly Leu Thr Gly Ser Val Glu

500 505 510

Phe Asp Gln Ala Lys Arg Asp Gly Lys Ile Asp Ile Thr Ile Pro Val

515 520 525

Ala Asn Leu Gln Ser Gly Ser Gln His Phe Thr Asp His Leu Lys Ser

530 535 540

Ala Asp Ile Phe Asp Ala Ala Gln Tyr Pro Asp Ile Arg Phe Val Ser

545 550 555 560

Thr Lys Phe Asn Phe Asn Gly Lys Lys Leu Val Ser Val Asp Gly Asn

565 570 575

Leu Thr Met His Gly Lys Thr Ala Pro Val Lys Leu Lys Ala Glu Lys

580 585 590

Phe Asn Cys Tyr Gln Ser Pro Met Ala Lys Thr Glu Val Cys Gly Gly

595 600 605

Asp Phe Ser Thr Thr Ile Asp Arg Thr Lys Trp Gly Val Asp Tyr Leu

610 615 620

Val Asn Val Gly Met Thr Lys Ser Val Arg Ile Asp Ile Gln Ile Glu

625 630 635 640

Ala Ala Lys Gln

<210> 17

<211> 364

<212> PRT

<213> Neisseria meningitidis

<400> 17

Met Ser Met Lys His Phe Pro Ser Lys Val Leu Thr Thr Ala Ile Leu

1 5 10 15

Ala Thr Phe Cys Ser Gly Ala Leu Ala Ala Thr Ser Asp Asp Asp Val

20 25 30

Lys Lys Ala Ala Thr Val Ala Ile Val Ala Ala Tyr Asn Asn Gly Gln

35 40 45

Glu Ile Asn Gly Phe Lys Ala Gly Glu Thr Ile Tyr Asp Ile Gly Glu

50 55 60

Asp Gly Thr Ile Thr Gln Lys Asp Ala Thr Ala Ala Asp Val Glu Ala

65 70 75 80

Asp Asp Phe Lys Gly Leu Gly Leu Lys Lys Val Val Thr Asn Leu Thr

85 90 95

Lys Thr Val Asn Glu Asn Lys Gln Asn Val Asp Ala Lys Val Lys Ala

100 105 110

Ala Glu Ser Glu Ile Glu Lys Leu Thr Thr Lys Leu Ala Asp Thr Asp

115 120 125

Ala Ala Leu Ala Asp Thr Asp Ala Ala Leu Asp Glu Thr Thr Asn Ala

130 135 140

Leu Asn Lys Leu Gly Glu Asn Ile Thr Thr Phe Ala Glu Glu Thr Lys

145 150 155 160

Thr Asn Ile Val Lys Ile Asp Glu Lys Leu Glu Ala Val Ala Asp Thr

165 170 175

Val Asp Lys His Ala Glu Ala Phe Asn Asp Ile Ala Asp Ser Leu Asp

180 185 190

Glu Thr Asn Thr Lys Ala Asp Glu Ala Val Lys Thr Ala Asn Glu Ala

195 200 205

Lys Gln Thr Ala Glu Glu Thr Lys Gln Asn Val Asp Ala Lys Val Lys

210 215 220

Ala Ala Glu Thr Ala Ala Gly Lys Ala Glu Ala Ala Ala Gly Thr Ala

225 230 235 240

Asn Thr Ala Ala Asp Lys Ala Glu Ala Val Ala Ala Lys Val Thr Asp

245 250 255

Ile Lys Ala Asp Ile Ala Thr Asn Lys Ala Asp Ile Ala Lys Asn Ser

260 265 270

Ala Arg Ile Asp Ser Leu Asp Lys Asn Val Ala Asn Leu Arg Lys Glu

275 280 285

Thr Arg Gln Gly Leu Ala Glu Gln Ala Ala Leu Ser Gly Leu Phe Gln

290 295 300

Pro Tyr Asn Val Gly Arg Phe Asn Val Thr Ala Ala Val Gly Gly Tyr

305 310 315 320

Lys Ser Glu Ser Ala Val Ala Ile Gly Thr Gly Phe Arg Phe Thr Glu

325 330 335

Asn Phe Ala Ala Lys Ala Gly Val Ala Val Gly Thr Ser Ser Gly Ser

340 345 350

Ser Ala Ala Tyr His Val Gly Val Asn Tyr Glu Trp

355 360

<210> 18

<211> 341

<212> PRT

<213> Neisseria meningitidis

<400> 18

Leu Ala Ala Thr Ser Asp Asp Asp Val Lys Lys Ala Ala Thr Val Ala

1 5 10 15

Ile Val Ala Ala Tyr Asn Asn Gly Gln Glu Ile Asn Gly Phe Lys Ala

20 25 30

Gly Glu Thr Ile Tyr Asp Ile Gly Glu Asp Gly Thr Ile Thr Gln Lys

35 40 45

Asp Ala Thr Ala Ala Asp Val Glu Ala Asp Asp Phe Lys Gly Leu Gly

50 55 60

Leu Lys Lys Val Val Thr Asn Leu Thr Lys Thr Val Asn Glu Asn Lys

65 70 75 80

Gln Asn Val Asp Ala Lys Val Lys Ala Ala Glu Ser Glu Ile Glu Lys

85 90 95

Leu Thr Thr Lys Leu Ala Asp Thr Asp Ala Ala Leu Ala Asp Thr Asp

100 105 110

Ala Ala Leu Asp Glu Thr Thr Asn Ala Leu Asn Lys Leu Gly Glu Asn

115 120 125

Ile Thr Thr Phe Ala Glu Glu Thr Lys Thr Asn Ile Val Lys Ile Asp

130 135 140

Glu Lys Leu Glu Ala Val Ala Asp Thr Val Asp Lys His Ala Glu Ala

145 150 155 160

Phe Asn Asp Ile Ala Asp Ser Leu Asp Glu Thr Asn Thr Lys Ala Asp

165 170 175

Glu Ala Val Lys Thr Ala Asn Glu Ala Lys Gln Thr Ala Glu Glu Thr

180 185 190

Lys Gln Asn Val Asp Ala Lys Val Lys Ala Ala Glu Thr Ala Ala Gly

195 200 205

Lys Ala Glu Ala Ala Ala Gly Thr Ala Asn Thr Ala Ala Asp Lys Ala

210 215 220

Glu Ala Val Ala Ala Lys Val Thr Asp Ile Lys Ala Asp Ile Ala Thr

225 230 235 240

Asn Lys Ala Asp Ile Ala Lys Asn Ser Ala Arg Ile Asp Ser Leu Asp

245 250 255

Lys Asn Val Ala Asn Leu Arg Lys Glu Thr Arg Gln Gly Leu Ala Glu

260 265 270

Gln Ala Ala Leu Ser Gly Leu Phe Gln Pro Tyr Asn Val Gly Arg Phe

275 280 285

Asn Val Thr Ala Ala Val Gly Gly Tyr Lys Ser Glu Ser Ala Val Ala

290 295 300

Ile Gly Thr Gly Phe Arg Phe Thr Glu Asn Phe Ala Ala Lys Ala Gly

305 310 315 320

Val Ala Val Gly Thr Ser Ser Gly Ser Ser Ala Ala Tyr His Val Gly

325 330 335

Val Asn Tyr Glu Trp

340

<210> 19

<211> 327

<212> PRT

<213> Neisseria meningitidis

<400> 19

Ala Thr Asn Asp Asp Asp Val Lys Lys Ala Ala Thr Val Ala Ile Ala

1 5 10 15

Ala Ala Tyr Asn Asn Gly Gln Glu Ile Asn Gly Phe Lys Ala Gly Glu

20 25 30

Thr Ile Tyr Asp Ile Asp Glu Asp Gly Thr Ile Thr Lys Lys Asp Ala

35 40 45

Thr Ala Ala Asp Val Glu Ala Asp Asp Phe Lys Gly Leu Gly Leu Lys

50 55 60

Lys Val Val Thr Asn Leu Thr Lys Thr Val Asn Glu Asn Lys Gln Asn

65 70 75 80

Val Asp Ala Lys Val Lys Ala Ala Glu Ser Glu Ile Glu Lys Leu Thr

85 90 95

Thr Lys Leu Ala Asp Thr Asp Ala Ala Leu Ala Asp Thr Asp Ala Ala

100 105 110

Leu Asp Ala Thr Thr Asn Ala Leu Asn Lys Leu Gly Glu Asn Ile Thr

115 120 125

Thr Phe Ala Glu Glu Thr Lys Thr Asn Ile Val Lys Ile Asp Glu Lys

130 135 140

Leu Glu Ala Val Ala Asp Thr Val Asp Lys His Ala Glu Ala Phe Asn

145 150 155 160

Asp Ile Ala Asp Ser Leu Asp Glu Thr Asn Thr Lys Ala Asp Glu Ala

165 170 175

Val Lys Thr Ala Asn Glu Ala Lys Gln Thr Ala Glu Glu Thr Lys Gln

180 185 190

Asn Val Asp Ala Lys Val Lys Ala Ala Glu Thr Ala Ala Gly Lys Ala

195 200 205

Glu Ala Ala Ala Gly Thr Ala Asn Thr Ala Ala Asp Lys Ala Glu Ala

210 215 220

Val Ala Ala Lys Val Thr Asp Ile Lys Ala Asp Ile Ala Thr Asn Lys

225 230 235 240

Asp Asn Ile Ala Lys Lys Ala Asn Ser Ala Asp Val Tyr Thr Arg Glu

245 250 255

Glu Ser Asp Ser Lys Phe Val Arg Ile Asp Gly Leu Asn Ala Thr Thr

260 265 270

Glu Lys Leu Asp Thr Arg Leu Ala Ser Ala Glu Lys Ser Ile Ala Asp

275 280 285

His Asp Thr Arg Leu Asn Gly Leu Asp Lys Thr Val Ser Asp Leu Arg

290 295 300

Lys Glu Thr Arg Gln Gly Leu Ala Glu Gln Ala Ala Leu Ser Gly Leu

305 310 315 320

Phe Gln Pro Tyr Asn Val Gly

325

<210> 20

<211> 202

<212> PRT

<213> Neisseria meningitidis

<400> 20

Met Lys Pro Lys Pro His Thr Val Arg Thr Leu Ile Ala Ala Ile Phe

1 5 10 15

Ser Leu Ala Leu Ser Gly Cys Val Ser Ala Val Ile Gly Ser Ala Ala

20 25 30

Val Gly Ala Lys Ser Ala Val Asp Arg Arg Thr Thr Gly Ala Gln Thr

35 40 45

Asp Asp Asn Val Met Ala Leu Arg Ile Glu Thr Thr Ala Arg Ser Tyr

50 55 60

Leu Arg Gln Asn Asn Gln Thr Lys Gly Tyr Thr Pro Gln Ile Ser Val

65 70 75 80

Val Gly Tyr Asn Arg His Leu Leu Leu Leu Gly Gln Val Ala Thr Glu

85 90 95

Gly Glu Lys Gln Phe Val Gly Gln Ile Ala Arg Ser Glu Gln Ala Ala

100 105 110

Glu Gly Val Tyr Asn Tyr Ile Thr Val Ala Ser Leu Pro Arg Thr Ala

115 120 125

Gly Asp Ile Ala Gly Asp Thr Trp Asn Thr Ser Lys Val Arg Ala Thr

130 135 140

Leu Leu Gly Ile Ser Pro Ala Thr Gln Ala Arg Val Lys Ile Val Thr

145 150 155 160

Tyr Gly Asn Val Thr Tyr Val Met Gly Ile Leu Thr Pro Glu Glu Gln

165 170 175

Ala Gln Ile Thr Gln Lys Val Ser Thr Thr Val Gly Val Gln Lys Val

180 185 190

Ile Thr Leu Tyr Gln Asn Tyr Val Gln Arg

195 200

<210> 21

<211> 178

<212> PRT

<213> Neisseria meningitidis

<400> 21

Ser Ala Val Ile Gly Ser Ala Ala Val Gly Ala Lys Ser Ala Val Asp

1 5 10 15

Arg Arg Thr Thr Gly Ala Gln Thr Asp Asp Asn Val Met Ala Leu Arg

20 25 30

Ile Glu Thr Thr Ala Arg Ser Tyr Leu Arg Gln Asn Asn Gln Thr Lys

35 40 45

Gly Tyr Thr Pro Gln Ile Ser Val Val Gly Tyr Asp Arg His Leu Leu

50 55 60

Leu Leu Gly Gln Val Ala Thr Glu Gly Glu Lys Gln Phe Val Gly Gln

65 70 75 80

Ile Ala Arg Ser Glu Gln Ala Ala Glu Gly Val Tyr Asn Tyr Ile Thr

85 90 95

Val Ala Ser Leu Pro Arg Thr Ala Gly Asp Ile Ala Gly Asp Thr Trp

100 105 110

Asn Thr Ser Lys Val Arg Ala Thr Leu Leu Gly Ile Ser Pro Ala Thr

115 120 125

Arg Ala Arg Val Lys Ile Val Thr Tyr Gly Asn Val Thr Tyr Val Met

130 135 140

Gly Ile Leu Thr Pro Glu Glu Gln Ala Gln Ile Thr Gln Lys Val Ser

145 150 155 160

Thr Thr Val Gly Val Gln Lys Val Ile Thr Leu Tyr Gln Asn Tyr Val

165 170 175

Gln Arg

<210> 22

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<400> 22

Gly Ser Gly Gly Gly Gly

1 5

<210> 23

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<400> 23

Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg

1 5 10

<210> 24

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<400> 24

Gly Ser Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg

1 5 10

<210> 25

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<400> 25

Gly Lys Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg

1 5 10

<210> 26

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<400> 26

Met Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg

1 5 10

<210> 27

<211> 3

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<400> 27

Met Ala Ser

1

<210> 28

<211> 8

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<400> 28

Leu Glu His His His His His His

1 5

<210> 29

<211> 769

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 29

Met Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg Val Ala Ala Asp

1 5 10 15

Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys

20 25 30

Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn

35 40 45

Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn

50 55 60

Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg

65 70 75 80

Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu

85 90 95

Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His Ser Ala Val Val

100 105 110

Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys Ile Asp Ser Leu

115 120 125

Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly Gly Glu His Thr

130 135 140

Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr His Gly Lys Ala

145 150 155 160

Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe

165 170 175

Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu Lys Thr Pro Glu

180 185 190

Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala Asp Glu Lys Ser

195 200 205

His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser Glu Glu Lys Gly

210 215 220

Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln Glu Ile Ala Gly

225 230 235 240

Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu Ile Gly Ile Ala

245 250 255

Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Thr

260 265 270

Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Gly

275 280 285

Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile Pro Gln Asn Gly Thr Leu

290 295 300

Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys Ala Gly Asp Lys

305 310 315 320

Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Ile Ser Arg

325 330 335

Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln Thr Ile Thr Leu

340 345 350

Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His Ser Ala Val Val

355 360 365

Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys Thr Asp Ser Leu

370 375 380

Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly Gly Glu His Thr

385 390 395 400

Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr His Gly Lys Ala

405 410 415

Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr Ser Ile Asp Phe

420 425 430

Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu Lys Thr Leu Glu

435 440 445

Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala Asp Glu Lys Ser

450 455 460

His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser Glu Glu Lys Gly

465 470 475 480

Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln Glu Ile Ala Gly

485 490 495

Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu Ile Gly Ile Ala

500 505 510

Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Ala

515 520 525

Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Gly

530 535 540

Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys Leu

545 550 555 560

Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp Ser

565 570 575

Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp Phe

580 585 590

Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser Gly

595 600 605

Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe Gln

610 615 620

Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala Lys

625 630 635 640

Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His Thr Ser Phe Asp

645 650 655

Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly Thr Ala Phe Gly

660 665 670

Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Ala Ala

675 680 685

Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu Asn

690 695 700

Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly Lys Arg His Ala

705 710 715 720

Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu Lys Gly Ser Tyr

725 730 735

Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val Ala Gly Ser Ala

740 745 750

Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala Lys

755 760 765

Gln

<210> 30

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 30

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 31

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<220>

<221> MOD_RES

<222> (240)..(240)

<223> any amino acid except Glu

<220>

<221> MOD_RES

<222> (496)..(496)

<223> any amino acid except Glu

<220>

<221> MOD_RES

<222> (543)..(543)

<223> any amino acid other than Arg

<400> 31

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Xaa

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Xaa

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Xaa Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 32

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 32

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Ala

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Ala

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Ser Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 33

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<220>

<221> MOD_RES

<222> (32)..(32)

<223> any amino acid other than Ser

<220>

<221> MOD_RES

<222> (123)..(123)

<223> any amino acid except Leu

<220>

<221> MOD_RES

<222> (285)..(285)

<223> any amino acid other than Ser

<220>

<221> MOD_RES

<222> (379)..(379)

<223> any amino acid except Leu

<400> 33

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Xaa

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Xaa Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Xaa Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Xaa Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 34

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 34

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Val

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Val Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 35

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<220>

<221> MOD_RES

<222> (32)..(32)

<223> any amino acid other than Ser

<220>

<221> MOD_RES

<222> (123)..(123)

<223> any amino acid except Leu

<220>

<221> MOD_RES

<222> (285)..(285)

<223> any amino acid other than Ser

<220>

<221> MOD_RES

<222> (379)..(379)

<223> any amino acid except Leu

<220>

<221> MOD_RES

<222> (543)..(543)

<223> any amino acid other than Arg

<400> 35

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Xaa

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Xaa Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Xaa Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Xaa Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Xaa Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 36

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 36

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Val

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Val Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Ser Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 37

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 37

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Val

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Ala

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Val Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Ala

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Ser Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 38

<211> 769

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 38

Met Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg Val Ala Ala Asp

1 5 10 15

Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys

20 25 30

Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Val Val Arg Lys Asn

35 40 45

Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn

50 55 60

Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg

65 70 75 80

Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu

85 90 95

Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His Ser Ala Val Val

100 105 110

Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys Ile Asp Ser Leu

115 120 125

Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly Gly Glu His Thr

130 135 140

Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr His Gly Lys Ala

145 150 155 160

Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe

165 170 175

Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu Lys Thr Pro Glu

180 185 190

Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala Asp Glu Lys Ser

195 200 205

His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser Glu Glu Lys Gly

210 215 220

Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln Glu Ile Ala Gly

225 230 235 240

Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Ala Ile Gly Ile Ala

245 250 255

Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Thr

260 265 270

Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Gly

275 280 285

Leu Lys Ser Leu Thr Leu Glu Asp Val Ile Pro Gln Asn Gly Thr Leu

290 295 300

Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys Ala Gly Asp Lys

305 310 315 320

Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Ile Ser Arg

325 330 335

Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln Thr Ile Thr Leu

340 345 350

Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His Ser Ala Val Val

355 360 365

Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys Thr Asp Ser Leu

370 375 380

Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly Gly Glu His Thr

385 390 395 400

Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr His Gly Lys Ala

405 410 415

Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr Ser Ile Asp Phe

420 425 430

Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu Lys Thr Leu Glu

435 440 445

Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala Asp Glu Lys Ser

450 455 460

His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser Glu Glu Lys Gly

465 470 475 480

Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln Glu Ile Ala Gly

485 490 495

Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Ala Ile Gly Ile Ala

500 505 510

Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Ala

515 520 525

Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Gly

530 535 540

Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Ser Lys Asn Glu Lys Leu

545 550 555 560

Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp Ser

565 570 575

Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp Phe

580 585 590

Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser Gly

595 600 605

Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe Gln

610 615 620

Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala Lys

625 630 635 640

Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His Thr Ser Phe Asp

645 650 655

Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly Thr Ala Phe Gly

660 665 670

Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Ala Ala

675 680 685

Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu Asn

690 695 700

Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly Lys Arg His Ala

705 710 715 720

Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu Lys Gly Ser Tyr

725 730 735

Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val Ala Gly Ser Ala

740 745 750

Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala Lys

755 760 765

Gln

<210> 39

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<220>

<221> MOD_RES

<222> (123)..(123)

<223> any amino acid except Leu

<220>

<221> MOD_RES

<222> (379)..(379)

<223> any amino acid except Leu

<400> 39

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Xaa Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Xaa Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 40

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 40

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 41

<211> 757

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic polypeptide "

<400> 41

Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro

1 5 10 15

Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser

20 25 30

Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys

35 40 45

Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

50 55 60

Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln

65 70 75 80

Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His

85 90 95

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

100 105 110

Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

115 120 125

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr

130 135 140

His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr

145 150 155 160

Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu

165 170 175

Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

180 185 190

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

195 200 205

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

210 215 220

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

225 230 235 240

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

245 250 255

Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

260 265 270

Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser Ile Pro Gln

275 280 285

Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys Thr Phe Lys

290 295 300

Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp

305 310 315 320

Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val Asp Gly Gln

325 330 335

Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asn His

340 345 350

Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys

355 360 365

Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Arg Val Ser Gly Leu Gly

370 375 380

Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys Ala Glu Tyr

385 390 395 400

His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg Leu His Tyr

405 410 415

Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile Glu His Leu

420 425 430

Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala

435 440 445

Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser

450 455 460

Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln

465 470 475 480

Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu

485 490 495

Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala

500 505 510

Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His

515 520 525

Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Ser Lys

530 535 540

Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly

545 550 555 560

Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser

565 570 575

Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr

580 585 590

Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu

595 600 605

Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys

610 615 620

Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His

625 630 635 640

Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly

645 650 655

Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile

660 665 670

Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser

675 680 685

Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly

690 695 700

Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu

705 710 715 720

Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val

725 730 735

Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly

740 745 750

Leu Ala Ala Lys Gln

755

<210> 42

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<220>

<221> variants

<222> (3)..(10)

<223 >/replace = ""

<220>

<221> features not yet classified

<222> (1)..(10)

<223 >/Note = "residues of variants given in sequence have no preference for those in the annotation of variant positions"

<400> 42

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly

1 5 10

<210> 43

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<220>

<221> variants

<222> (4)..(10)

<223 >/replace = ""

<220>

<221> features not yet classified

<222> (1)..(10)

<223 >/Note = "residues of variants given in sequence have no preference for those in the annotation of variant positions"

<400> 43

His His His His His His His His His His

1 5 10

<210> 44

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<221> sources

<223 >/note = "description of artificial sequence: synthetic peptide "

<220>

<221> variants

<222> (5)..(10)

<223 >/replace = ""

<220>

<221> features not yet classified

<222> (1)..(10)

<223 >/Note = "residues of variants given in sequence have no preference for those in the annotation of variant positions"

<400> 44

His His His His His His His His His His

1 5 10